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INVESTIGATING THE IMPACT OF NRMT1 CANCER MUTANTS ON 
CATALYTIC SPECIFICITY AND THE DNA DAMAGE RESPONSE 
 
Kaitlyn Marie Shields 
June 22, 2018 
 
Protein methylation is an established and critical 
posttranslational modification controlling multiple 
cellular events.  Alterations in protein methylation have 
been implicated in many diseases, including cancer.  My 
work focused on the N-terminal trimethylase NRMT1 and the 
N-terminal monomethylase NRMT2.  Previous work proposed 
that NRMT2 assists NRMT1 by priming its substrates for 
trimethylation.  Importantly, NRMT1 mutations have been 
found in cancers, and loss of NRMT1 has been shown to 
promote oncogenic phenotypes in cancer cells.  Together, 
this suggests that altered activities of NRMT1/2 may play a 
role in cancer progression.  Although NRMT1/2 are 50% 
identical, they differ in key aromatic residues in their 
 vi	
active site.  Interestingly, mutation of the corresponding 
aromatic residues in the methyltransferase EZH2 (B-cell 
lymphoma) changes its activity from a monomethylase to a 
trimethylase, conferring oncogenicity.  Therefore, I 
hypothesized that the differences in these aromatic 
residues are responsible for the distinct catalytic 
activities of NRMT1/2.  I also proposed that NRMT1 cancer 
mutations are responsible for oncogenic phenotypes.  My 
work illustrates that while aromatic residue mutations had 
no catalytic effect, both NRMT1 cancer mutants N209I 
(endometrial) and P211S (lung) displayed decreased 
trimethylase and increased mono-/dimethylase activity.  
These mutations are located in the peptide-binding channel 
and suggest there may be a second structural region 
impacting enzyme specificity.  The mutants also required 
greater time and substrate levels to be comparable to WT 
NRMT1.  Furthermore, in a cellular context lacking 
endogenous NRMT1, the N209I and P211S mutants were 
incapable of rescuing trimethylation levels or 
proliferation.  Additional preliminary studies suggested a 
potential role for NRMT1 in the DNA damage response 
pathway.  However, further studies will be required to shed 
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CHAPTER I: INTRODUCTION 
POSTTRANSLATIONAL MODIFICATIONS AND THEIR IMPACT ON 
MOLECULAR INTERACTIONS AND GENE EXPRESSION 
 
The human genome is predicted to encode approximately 
20,000 genes (1-3).  However, the human proteome is 
invariably more complex due to post-transcriptional (namely 
alternative splicing) and post-translational events.  Such 
events allow a single gene to give rise to multiple protein 
species, resulting in a proteome that is considerably more 
immense and diverse than the accompanying genome.  One 
prominent example involves posttranslational modifications 
(PTMs) that occur on proteins. 
PTMs are covalent modifications that can regulate 
protein function through various means, including activity, 
enzymatic activation/inactivation, subcellular 
localization, as well as protein-protein and protein-DNA 
interactions (4-8).  The list of PTMs is extensive, and 
includes methylation, acetylation, phosphorylation, 
glycosylation, ubiquitination, sumoylation, hydroxylation, 
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sulfation, nitrosylation, palmitoylation, as well as a host 
of infrequent modifications (4,9-12). 
As an example, histones are known to be acetylated, 
phosphorylated, methylated, and ubiquitinated (13-16).  
These modifications exhibit great clout over transcription, 
often by directing chromatin remodeling proteins to open or 
close the conformation of the chromatin (17).  One primary 
effect of this is increased or decreased accessibility of 
transcription factors – whether enhancers or silencers – to 
the chromatin, leading to the augmentation or repression of 
gene expression (18). 
Histone acetylation and phosphorylation are mainly 
associated with transcriptional activation (13,15).  
Contrastingly, the effect of methylation and ubiquitination 
of histones is dichotomous.  While the ubiquitination of 
histone H2A is linked with transcriptional repression, the 
ubiquitination of histone H2B is linked with 
transcriptional activation (19).  Likewise, the methylation 
of histone H3 lysine 4 and H3 lysine 36 (H3K4, H3K36) is 
correlated with activation; while others are correlated 
with repression (i.e. H3K27, H4K20) (20-26).  Thus, unlike 
DNA methylation, not all histone methylation events are 
repressive. 
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Besides the modification of histones, PTMs also occur 
on the side chains of non-histone proteins, as well as on 
the N- or C-termini of proteins (27-31).  This dissertation 
will focus on those that occur at the N-terminus, while 
information for a handful of other PTMs can be found in 




N-terminal posttranslational modifications can occur 
on the alpha amino group of the initiating methionine, or 
on the new alpha amino group if the initiator methionine is 
first cleaved by a methionine aminopeptidase (7).  Although 
N-terminal methionine excision (NME) is typical for N-
terminal PTMs, that is not always the case (41).  
Currently, the reported N-terminal PTMs include 
methylation, acetylation, propionylation, ubiquitination, 
palmitoylation, and myristoylation (6,7,42). 
N-terminal myristoylation and palmitoylation result 
from the addition of a myristic or palmitic acid, by N-
terminal myristoyltransferases or 
palmitoylacyltransferases, respectively (7).  This occurs 
via the donor molecules myristoyl-CoA or palmitoyl-CoA, 
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leading to the attachment of the fatty acid to an N-
terminal Gly residue of their substrates. 
Propionylation is a recently identified N-terminal 
PTM, which is the addition of a molecule derived from 
propionic acid.  Currently, less than 20 proteins have been 
described to harbor this modification (7).  Unexpectedly, 
the enzyme that catalyzes this reaction is the N-terminal 
acetyltransferase complex NatA, demonstrating a role for 
this enzyme outside of N-terminal acetylation (6,7). 
N-terminal ubiquitylation adds a ubiquitin protein to 
the free amine of the first N-terminal residue of the 
target protein (7).  Like internal polyubiquitylation of 
internal residues, E2 and E3 ubiquitin ligase enzymes are 
also required.  While internal ubiquitination is most 
recognized for its involvement in proteasomal degradation 
of target proteins, it also serves in other biological 
processes, including the DNA damage response and acting as 
a second messenger molecule in signaling pathways (14).  
Although N-terminal ubiquitylation has been studied less 
than its internal counterpart, the N-terminal modification 
presumably also has roles in the aforementioned processes. 
N-terminal acetylation is the transfer of an acetyl 
moiety from acetyl-CoA to the amine of the N-terminal 
residue of a protein by an N-terminal acetyltransferase 
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(NAT) (7,42).  NATs recognize the consensus sequence 
(Q/R)XXGXX(G/A) (7).  Interestingly, the six different NAT 
enzyme subtypes differ in their preference for the 
initiating methionine, or the N-terminal residue resultant 
from methionine cleavage, indicating subtle differences in 
substrate specificity.  Four of the subtypes acetylate the 
initiating methionine residue, while the other two 
acetylate the N-terminal residue resultant from methionine 
cleavage (6).  The addition of acetyl to the N-terminus 
changes its positive charge to neutral, which can affect 
protein-protein interactions (6,43). 
Some examples of N-terminal acetylation targets 
include histone H2A and H4, as well as the H3 variant CENP-
A (6,20).  This modification occurs in the cytoplasm, and 
is necessary for functions such as subcellular localization 
and protein stability (6).  To date, an N-terminal 
deacetylase has not been discovered, so it is considered to 
be an irreversible PTM (6,7).  Contrary to the long-held 
dogma that a protein could only be N-terminally acetylated 
or methylated (and never the other in a different cellular 
context, for example), N-terminal acetylation and N-
terminal methylation do not preclude each other.  This is 
evidenced by MYL9, and other proteins, which have been 
reported to undergo either modification (42,44,45). 
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Similar to most biological methylation reactions, the 
methyl added to the N-terminus comes from the methyl donor 
S-Adenosyl methionine (SAM, or AdoMet).  Although N-
terminal methylation has been documented for decades, 
enzymes responsible for this process have only been 
discovered in the past 10 years (46,47).  NRMT (N-terminal 
RCC1 Methyltransferase, also known as NRMT1) was first 
discovered in 2010 (47), and subsequently, its homologue 
NRMT2, was characterized three years later (46).  Like N-
terminal acetylation, an N-terminal demethylase has also 
yet to be identified (6).  As NRMT is the main thrust of 
this dissertation, it will be discussed in more detail 
below. 
 
EFFECTS OF PROTEIN METHYLATION 
 
Although phosphorylation and acetylation have been 
studied most extensively, protein methylation is also a 
critical and common PTM that can regulate protein function.  
Indeed, this PTM plays crucial roles in chromatin 
stability, DNA repair, and transcriptional regulation 
(48,49).  N-terminal methylation, specifically, has been 
established as a regulator of the DNA damage response and 
protein-DNA interactions (6,20,50-52). 
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Proteins can be mono-, di-, and trimethylated.  Each 
methylation state has a distinct functional readout, 
dependent upon the lysine or arginine residue methylated, 
as well as the state of methylation (22,48,53-56).  
Therefore, methylation of the same residue, yet differing 
in methylation state, often confers distinctive functions.  
For instance, mono- and trimethylation of histone H4 lysine 
20 (H4K20) are means of transcriptional regulation.  
Monomethylation of H4K20 promotes transcriptional 
elongation, while trimethylation of the same residue pauses 
transcription (RNA Polymerase II pausing) (22).  This is a 
testament to the cooperation of distinct histone 
modifications and subsequent transcriptional effects, as 
proposed by Brian Strahl and David Allis in the histone 
code hypothesis (49). 
When H4K20 becomes monomethylated by SETD8 (SET domain 
containing protein 8), the MSL (male-specific lethal) 
complex is recruited to gene promoters.  Consequently, 
H4K16 is acetylated by MSL, leading to the phosphorylation 
of Ser 2 on the C-terminal domain (CTD) of RNA Polymerase 
II (Pol II), and releasing it from a paused state into 
active transcriptional elongation (22).  On the other hand, 
trimethylation of H4K20 by Suv420H2 precludes recruitment 
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of the MSL complex, and thus, prevents the acetylation of 
H4K16 and the subsequent CTD phosphorylation (22). 
A handful of signaling pathways are also regulated by 
protein methylation, including the RAS-RAF and Wnt 
signaling pathways.  For example, in the Wnt signaling 
pathway, the methyltransferases PRMT1 and PRMT7 methylate 
the GTPase-activating protein G3BP2, leading to downstream 
kinase recruitment and eventual b-catenin activation (21). 
The biological impacts or regulation propagated via 
protein methylation are partly due to the crosstalk between 
the methylation and other PTMs (i.e. the histone code 
hypothesis) (21,49).  Its effects are also brought about by 
an induction of a positive charge on the nitrogen of the 
target residue; whether a positive charge is induced is 
dependent on the residue methylated, N-terminal or internal 
side chain methylation, and methylation state.  This change 
in charge can easily disrupt or change the partners with 
which the methylation target interacts, which can have 
further downstream effects (32,57). 
 
READERS, WRITERS, AND ERASERS 
 
The terms “Readers,” “Writers,” and “Erasers” are 
often used to described various regulators of the PTM 
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process.  Readers are the proteins that recognize and bind 
to the protein at its site of modification; writers are the 
enzymes which perform the modification; and the erasers are 
the enzymes which remove the PTM.  Here, I will only 
discuss readers, writers, and erasers as they pertain to 
methylation.  Lastly, to clarify, substrate specificity 
refers to an enzyme’s selectivity for an individual 
substrate over another (i.e. Rb over p53).  Catalytic 
specificity, however, refers to an enzyme’s differentiation 
among different methylation states: whether the enzyme is 
able to mono-, di-, or trimethylate its substrate (i.e. 
specificity or differentiation for monomethylation over 
trimethylation). 
As stated previously, writers are the enzymes that add 
the PTM to the substrate.  For N-terminal methylation, the 
known enzymes are NRMT1 and NRMT2 (46,47).  However, for 
histone and internal side chain methylation, a host of 
writer enzymes are known (58-62).  Some histone 
methyltransferases are specific to their histone targets, 
but numerous writers also have non-histone substrates (58-
60).  Some histone methyltransferases can have the 
catalytic specificity for only monomethylation, while 
others may have the specificity for all three methylation 
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states, or any combination of the three 
(22,24,25,55,61,63,64). 
The most common methyltransferases are lysine 
methyltransferases and arginine methyltransferases 
(16,56,58,65-67).  While many lysine methyltransferases are 
known by other names, they are generally referred to as the 
KMT (lysine methyltransferase) enzymes (68-71).  The family 
members include KMT1-8, with each member having multiple 
enzyme sub-family members (16).  Within the KMT family, 
catalytic specificities range widely (16).  The arginine 
methyltransferases are known as PRMTs (protein arginine 
methyltransferases) and consist of PRMT1-9 (72).  All PRMTs 
mono- and dimethylate substrates; there is no arginine 
trimethylation (72).  These are either classified as type I 
(asymmetric dimethylation) or type II (symmetric 
dimethylation) (72).  Asymmetric dimethylation is 
asymmetric as both methyl groups are found on the same 
nitrogen atom, found at the end of the arginine side chain 
(72).  Symmetric dimethylation is symmetric as one methyl 
group each is placed onto two different nitrogen atoms at 
the end of the arginine side chain (72). 
As previously stated, there is no known eraser for N-
terminal methylation, as an N-terminal demethylase has yet 
to be discovered (7).  In contrast, various other lysine 
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demethylases (KDMs) have been identified.  The LSD1 
(lysine-specific histone demethylase 1) family members are 
FAD-dependent enzymes that can remove lysine mono- and 
dimethylation through oxidation (73,74).  The JmjC (Jumonji 
C)-domain containing demethylases, though, are iron- and 2-
oxoglutarate-dependent, and remove all three methylation 
states via hydroxylation (16,74,75).  Thus far, no enzyme 
has been identified to directly remove arginine 
methylation.  In this case, methylated arginines are 
converted into citrullines by deimination (66). 
PTM functional readouts are generally accomplished by 
the readers, which contain PTM-specific recognition domains 
(64,76,77).  Several domains are capable of lysine and 
arginine methylation recognition, including the 
chromodomain, Tudor, PHD, MBT, and PWWP domains (76,78-81).  
Reader domains recognize a specific methylation state (or 
states) on a precise residue, and some domains recognize 
more than one substrate (64,76-81).  The different 
substrate specificities and/or different methylation state 
recognition among reader proteins is due to structural 
differences, specifically, the presence of different 
residues critical to methyl binding (64,76,77,82). 
The methylation recognition leads to recruitment of 
protein complexes, such as chromatin remodeling complexes, 
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transcription factors, or DNA repair proteins (22,24,53-
55).  These complexes usually open up (or close) the 
chromatin by sliding and repositioning nucleosomes on the 
DNA (83), which will lead to further recruitment of 
transcription factors, or other proteins, downstream.  One 
common class of chromatin remodeling complexes is known as 
Mi2/NURD.  This complex has a methylation associating 
chromodomain, which has a transcriptionally repressive 
effect (84,85).  As such, the reader is ultimately 
responsible for the functional outcome of the PTM. 
 
BIOLOGICAL IMPACT OF ALTERED METHYLATION LEVELS 
 
The physiological importance of protein methylation 
has been illustrated by multiple studies involving genetic 
manipulation of mice (24,63,86-89).  For example, the 
conditional knockout of one or both Suv4-20h histone 
methyltransferases (responsible for di- and trimethylation 
of H4K20) in mice results in perinatal lethality.  Double 
knockout animals exhibit a dramatic increase in 
monomethylation, and a near loss of di- and trimethylation.  
Furthermore, primary mouse embryonic fibroblasts derived 
from these double knockout animals exhibit decreased 
cellular proliferation as well as a heightened sensitivity 
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to DNA damage (24).  This drastic shift in methylation 
likely impairs the DNA damage response, as the aberrant 
methylation impacts recruitment of DNA damage proteins, 
such as 53BP1, to sites of damage with double strand breaks 
(DSBs) (24). 
In yeast, the DNA checkpoint mediator protein Crb2 
becomes localized to sites of DNA damage, and associates 
with H4K20 dimethylation.  In cells lacking this 
dimethylation, the recruitment of Crb2 to DNA damage is 
abolished, resulting in impaired checkpoint function (53).  
In another example, SET8 depletion in Drosophila, and the 
subsequent loss of H4K20 monomethylation, has been shown to 
be detrimental to cell viability, nucleosome dynamics, and 
nuclear arrangement (61). 
Altered methylation patterns have also been 
demonstrated to play a role in many cancers, including 
leukemia, lymphoma, lung cancer, and breast cancer, among 
others (63,87-90).  Half of acute myeloid leukemia (AML) 
patients exhibit abnormal expression of HOX genes (86).  
This dysregulated expression prevents recruitment of the 
transcription factor AF10, which interacts with the H3K79 
histone methyltransferase DOT1L and helps facilitate the 
methylation of H3K79 (86).  The lack of AF10 recruitment 
inhibits the di- and trimethylation of H3K79, leading to 
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appropriately low (or no) HOX gene expression (86,91).  The 
interaction between AF10 and DOT1L is crucial for leukemic 
oncogenic transformation, as the deletion or inhibition of 
either AF10 or DOT1L inhibits the transformation, and 
increases mouse survival in xenograft assays (86).  
Importantly, this has been attributed to a reduction in the 
di- and trimethylation of H3K79 at HOX genes (86). 
 
DNA DAMAGE AND REPAIR 
 
 The eukaryotic DNA replication machinery is a large 
complex of proteins that include the DNA polymerases.  
Despite the high fidelity of polymerases, replication 
errors sporadically occur (92).  When a nucleotide is 
erroneously incorporated, it is removed by the 3’ à 5’ 
exonuclease activity of the polymerase (93). 
Despite this proofreading mechanism, these errors are 
not always repaired, resulting in a mutation – a change in 
the DNA sequence of the gene.  The occurrence of mutations, 
regardless of the cause or source, are completely random 
(92).  Insertion/deletion (indel) mutations, additional 
insertions or deletions of base pairs, can also occur, 
resulting in a frameshift.  Because they change the number 
of bases in the open reading frame, this damage to the DNA 
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will alter the triplet codons, and therefore the amino 
acids specified by them, giving rise to potentially 
deleterious mutations to the protein product of the gene. 
However, even if the polymerase error is not detected 
by the proofreading exonuclease function, the mistake can 
still be corrected through mismatch repair (MMR).  In 
eukaryotes, MMR involves numerous MutS and MutL proteins, 
the endonucleolytic removal of the erroneous base pairs, 
which will be subsequently filled in by DNA polymerases 
(94).  
 Besides replication errors that are continually 
propagated this way (assuming they have gone undetected by 
all mechanisms of proofreading and correction), or passed 
down to offspring, DNA damage also occurs by environmental 
factors or chemical mutagen carcinogens.  A chemical 
mutagen is a carcinogen only if the induced mutation 
results in a phenotypic alteration. 
Two of the most common environmental factors causing 
DNA damage are cigarette smoke and ultraviolet light (92).  
This commonly induces the formation of pyrimidine dimers, 
especially thymine dimers, or other lesions such as bulky 
DNA adducts (95).  These dimers and adducts locally distort 
the DNA, interfering with replication (92).  In prokaryotes 
and some eukaryotes, damage such as thymine dimers can be 
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repaired outside of DNA excision and filling in the gap 
(92).  This process is called photoreactivation, which is 
carried out by DNA photolyases.  Humans do not contain DNA 
photolyase homologues (92).  Photoreactivation works by 
absorption of UV light by the photolyase, and reduction of 
FADH- and the pyrimidine dimer, effectively severing the 
dimer lesion (96). 
Damaged nucleotides which cannot be fixed by direct 
repair mechanisms, particularly photoreactivation, can be 
corrected by base excision repair (BER).  BER extracts the 
damaged base by DNA glycosylases, which split the 
glycosidic bond between the nitrogenous base and 
deoxyribose sugar (92).  An AP endonuclease then cleaves 
and removes the remaining deoxyribose sugar along with a 
few surrounding nucleotides.  The final correctional steps 
are filling in the resulting void by DNA polymerase and 
sealing the new bases in by DNA ligase (97,98). 
After generation of these environmentally propagated 
bulky DNA lesions, the repair mechanism routinely employed 
in humans (as we do not have DNA photolyase homologues) is 
nucleotide excision repair (NER) (92).  Xeroderma 
pigmentosum patients are acutely susceptible to these 
insults due to mutations in components of the NER system 
(99).  NER entails the recruitment of several factors such 
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as DDB1 and DDB2 (a NRMT1 target), coordinated by PARP1, 
nucleolytic excision of the lesion and immediately 
surrounding DNA, which is filled in by DNA polymerase 
(100). 
Damage by chemical mutagens usually falls under one of 
two broad categories: point mutations or indel mutations 
(described above) (92).  Point mutations are the 
replacement of a base with a different base; these 
mutations are sub-divided into transitions and 
transversions.  A transition mutation is the replacement of 
a purine (or pyrimidine) base with another purine (or 
pyrimidine) base (e.g. adenine for guanine, or thymine for 
cytosine).  A transversion mutation, however, is the 
replacement of a purine (or pyrimidine) base for a 
pyrimidine (or purine) base (e.g. guanine for cytosine). 
DNA intercalating agents can create indel mutations.  
Ethidium bromide is one such common intercalating agent, 
and it is frequently used to visualize DNA in gel 
electrophoresis.  The local distortion caused by the 
incorporation of the intercalating agent often leads to the 
insertion or deletion of a nucleotide during replication 
(92,101). 
In addition to these point mutation base swaps, 
reactive oxygen species (ROS) can oxidize bases.  Guanine 
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is commonly oxidized to 8-oxoguanine, which can pair with 
cytosine or adenine, leading to a point mutation 
transversion from G • C à T • A (92). 
All forms of DNA repair discussed thus far are 
mechanisms mobilized for single strand mutations and 
lesions.  DNA double-strand breaks (DSBs) are rectified by 
nonhomologous end-joining (NHEJ) or homologous 
recombination (92).  The homologous proteins Ku70 and Ku80 
detect DSBs in eukaryotes (92,102).  In NHEJ, the broken 
DNA strands must be realigned, facilitated by Ku70 and Ku80 
(92).  After the strands have been realigned, nucleotides 
must be either removed by nucleases or filled in by DNA 
polymerase.  Finally, the strands will be ligated by DNA 
ligase.  NHEJ is not a perfect solution, as nucleolytic 
removal causes mutations (92). 
Homologous recombination is an important step in 
meiosis.  As a repair mechanism, recombination can repair 
DSBs through homologous end-joining.  In this process, the 
normal, undamaged sister chromatid serves as the repair 
template (103).  Holliday junctions are formed, which 
involves the Rad51 protein, and the broken DNA strands 
intersect each other in these junctions.  Following this 
intersection, DNA polymerase closes the breakage points, 
which is sealed by DNA ligase (92).  Unlike NHEJ, 
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homologous end-joining is not error-prone and does not 
result in mutations because it uses the correct and intact 
sister chromatid as the template for repair (103).  
Moreover, homologous recombination can also be used to 
correct an impaired replication fork (92). 
 
SET DOMAINS AND EZH2 
 
As methylation governs such diverse processes, 
altering methylation levels, or the degree of methylation, 
can be deleterious.  Recent work demonstrated that a subset 
of B-cell lymphoma patients has mutations in the H3K27 
methyltransferase EZH2 – the catalytic component of the 
polycomb repressive complex 2 (PRC2) (104,105).  These 
mutations occur in aromatic residues in a region 
surrounding the active site known as the aromatic cage, and 
many of these residues are conserved in the majority of 
methyltransferases (105).  EZH2 contains the evolutionarily 
conserved SET domain, which is a catalytic domain of 
approximately 130 residues found in the majority of 
methyltransferases (106). 
One important feature of the SET domain is the lysine 
access channel.  This connects the sites of cofactor 
binding as well as substrate binding (106,107).  Several 
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aromatic amino acids comprise this region, and the size of 
the channel resolves whether the methyltransferase can 
mono-, di-, or trimethylate substrates, or any combination 
of the three states (106,107).  Noteworthy 
methyltransferase exceptions which do not contain a SET 
domain include the H3K79 methyltransferase DOT1L, as well 
as NRMT1 and NRMT2.  NRMT1 and NRMT2 are Class I Rossmann-
like fold methyltransferases (108-110). 
EZH2 is crucial for proliferation and has been 
implicated in cancer for years (105,111-114).  A handful of 
mutations of an evolutionarily conserved tyrosine residue 
within the SET domain of EZH2, Y641, were found in patient 
samples, including Y641F and Y641N (105).  These mutations, 
as well as Y641C studied by another group (115), result in 
a shift in the H3K27 methylation pattern, promoting 
primarily trimethylation over monomethylation (105).  As 
the aromatic cage determines the catalytic specificity of 
EZH2, the Y641 mutation changes the size of its aromatic 
cage, and thus its catalytic specificity (105).  From that 
study, mutant EZH2 had the highest in vitro enzymatic 
activity on dimethylated H3K27 peptide substrate (forming 
trimethylated H3K27 peptide substrate), while for wild type 
(WT), the enzymatic activity was lowest (105).  Besides the 
resultant shift in methylation state, transcriptional 
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profiles were found to be altered, with ensuing effects 
such as increased proliferation and colony formation 
(anchorage-independent growth) (105,111). 
 
NRMT AND RCC1 
 
My work focuses on the homologous N-terminal 
methyltransferases NRMT1 (N-terminal regulator of chromatin 
condensation methyltransferase 1) and NRMT2 (N-terminal 
regulator of chromatin condensation methyltransferase 2).  
Following cleavage of the initiator methionine on target 
proteins, NRMT1 and NRMT2 methylate the α-amine of the 
subsequent N-terminal residue (46,47).  They differ in 
catalytic specificity in that NRMT2 is only a 
monomethylase, while NRMT1 is a distributive trimethylase, 
capable of performing all three states of methylation 
(46,47).  Since NRMT1 is a distributive trimethylase, it 
binds its substrate and adds one methyl group at a time, 
dissociating from the substrate after the addition of each 
methyl group (46).  Being a monomethylase, NRMT2 aids in 
this process by adding the first methyl group to the 
substrate, resulting in substrates that can be more quickly 
trimethylated by NRMT1 (46). 
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NRMT1 (also known as METTL11A, or NTMT1) and NRMT2 
(also known as METTL11B) are 25-kD and 32-kD, respectively.  
They share 50% sequence identity and 75% sequence 
similarity (44,46) (Fig. 1).  In addition, their substrates 
possess an N-terminal X-P-(K/R) consensus sequence.  X can 
be any amino acid other than tryptophan, isoleucine, 
leucine, aspartate, or glutamate (46).  P is typically any 
polar or nonpolar amino acid (no charged amino acids), and 
lysine or arginine is accepted in the third position (44). 
Based on the NRMT consensus sequence, it was predicted 
that these methyltransferases target over 300 substrates 
(44,50).  A handful of these putative substrates have been 
identified and experimentally verified, including the 
following: RCC1 (regulator of chromatin condensation 1), 
Rb, SET, PARP3 [poly(ADP-ribose) polymerase 3], CENP-A 
(centromere protein A) (116), CENP-B (centromere protein 
B), DDB2 (damaged DNA-binding protein 2), KLHL31 (kelch-
like protein 31), RPL23A (ribosomal protein L23a), and MYL3 
(myosin light polypeptide 3) (20,46,47,50,52,117-119). 
RCC1 is a 45-kD protein, and the first identified 
substrate to be N-terminally methylated by NRMT1 (47).  It 
is the only identified guanine-nucleotide exchange factor 
for the Ran GTPase, and is vital for cytoplasmic-nuclear 







Figure 1. Protein sequence alignment of human NRMT1 and 
NRMT2. 
Sequence alignment shown for NRMT1 and truncated NRMT2 
(NRMT2 shown without the flexible N-terminal domain not 
found in NRMT1).  The amino acid sequences of NRMT1 and 
NRMT2 are 50% identical and 75% similar.  Identical 
residues are highlighted in black, and similar residues are 




mitotic spindle assembly, and chromatin association through 
binding DNA and histones H2A and H2B (120-125). 
Nuclear localization of RCC1 is crucial for 
interphase, and the N-terminal methylation of RCC1 is 
essential for its association with chromatin, as well as 
proper mitotic function and mitotic spindle formation 
(47,120,121).  This is evidenced by data showing that the 
loss of NRMT1 (loss of RCC1 methylation), or the presence 
of methylation-defective RCC1 mutants, causes reduced 
chromatin association of RCC1 (decreased DNA binding) 
during mitosis, giving rise to an abnormal multi-spindle 
phenotype (as opposed to normal bipolar spindle formation 
in mitosis) (47,120). 
As stated before, unlike EZH2, NRMT1 and NRMT2 do not 
harbor SET domains (108-110).  Importantly though, the 
aromatic cage residues of NRMT1 and NRMT2 are conserved 
with respect to EZH2.  Given this, I hypothesized that the 
shape and size of their aromatic cages may similarly 
dictate the catalytic specificities of NRMT1 and NRMT2.  
Likewise, I postulated that mutation of these aromatic cage 
residues in NRMT1 and NRMT2 can therefore alter their 
catalytic specificities. 
It has also been shown that NRMT1 depletion results in 
oncogenic phenotypes such as increased proliferation, cell 
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invasion and migration, and an increased sensitivity to DNA 
damaging agents (50,51).  These phenotypes suggest that 
monomethylation by NRMT2 alone is insufficient to 
functionally compensate for the loss of trimethylation 
(50,51). 
Importantly, mutations of both NRMT1 and NRMT2 are 
found in numerous human cancers (COSMIC, Catalogue of 
Somatic Mutations in Cancer database), and I was interested 
in determining if any of these mutations result in a 
shifted degree of N-terminal methylation, similar to the 
EZH2 mutations.  I therefore hypothesized that mutations in 
or around these aromatic residues in NRMT1 and NRMT2 would 
shift the degree of N-terminal methylation via altered 
catalytic specificity.  This hypothesis is addressed by aim 
1, or Chapter II. 
Determining which cancer mutations shift the levels of 
N-terminal methylation will help to determine their 
importance to oncogenicity.  Biochemical characterization 
of the mutations is therefore the first step towards that 
goal.  Studying mutations of the conserved aromatic cage 
residues can also tell us whether these residues, or an 
alternate structural motif, contribute to the catalytic 
specificity of NRMT1 and NRMT2. 
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As previously mentioned, the loss of NRMT1 results in 
oncogenic phenotypes such as increased proliferation, cell 
invasion and migration, anchorage-independent growth, as 
well as an increased sensitivity to DNA damaging agents 
(50,51).  NRMT1 must therefore be crucial for survival, or 
repair, in response to DNA damage.  NRMT1 knockout mice 
also exhibit premature aging phenotypes, formation of 
necrotic livers and polycystic ovaries, altered metabolism, 
and their MEFs (mouse embryonic fibroblasts) manifest an 
increased sensitivity to oxidative damage (51). 
I was thus interested in determining the degree of N-
terminal methylation conferred by mutations of NRMT1 and 
NRMT2, which is detailed in Chapter II.  Given the 
sensitivity of NRMT1-depleted cells to DNA damaging agents, 
I hypothesized that altered N-terminal methylation patterns 
would have an impact on cellular proliferation, as well as 
the DNA damage response.  This hypothesis is addressed by 







CHAPTER II: SELECT HUMAN CANCER MUTANTS OF NRMT1 ALTER ITS 





Lysine methylation is an important posttranslational 
modification (PTM) for regulating protein function.  This 
PTM plays crucial roles in chromatin organization, DNA 
repair, and transcriptional regulation (48,49).  The ε-amino 
groups of lysine side chains can be mono-, di-, and 
trimethylated, and each methylation state has a distinct 
functional readout, dependent upon the residue methylated 
(22,48,53-56).  These functional readouts are generally 
accomplished by reader proteins, which contain PTM-specific 
recognition domains (64,76,77).  Readers binding to 
methyllysine commonly have chromatin organization modifier 
domains (chromodomains), but can also contain Tudor, MBT, 
PWWP, PHD finger domains or Ankyrin or WD repeats (126).  
These methyllysine binding domains are specific for 
distinct lysine residues and distinct methylation states 
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(mono-, di-, or tri-) (127).  Recognition of methylated 
lysines by methyllysine readers leads to recruitment of 
protein complexes, such as chromatin-remodeling complexes, 
transcriptional machinery, or DNA repair holoenzymes 
(22,24,53-55). 
As methylation governs such diverse processes, 
altering methylation levels, or the degree of methylation, 
can be deleterious.  Recent work demonstrated that a subset 
of B-cell lymphoma patients have dominant mutations in the 
histone H3 lysine 27 (H3K27) methyltransferase EZH2, the 
catalytic component of the polycomb repressive complex 2 
(PRC2) (104,105).  These mutations occur in residues that 
create an aromatic cage in the active site and are 
conserved in the majority of methyltransferases (105).  One 
of the most commonly mutated residues in EZH2 is tyrosine 
641 (Y641) (105).  Mutation of this tyrosine to 
phenylalanine (Y641F) or asparagine (Y641N) shifted the 
H3K27 methylation pattern, promoting trimethylation over 
monomethylation (105).  The dominant Y641 mutations changed 
the size of the EZH2 aromatic cage, and thus altered its 
catalytic specificity (105).  As a result of the shift in 
methylation state, transcriptional profiles were altered, 
and cellular proliferation rates and colony formation 
ability increased (105,111). 
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N-terminal methylation of the free α-amino group is 
another type of protein methylation, and it has been 
established as a regulator of protein-DNA interactions 
(120).  Loss of N-terminal methylation of regulator of 
chromatin condensation 1 (RCC1) results in its 
mislocalization from chromatin and multi-polar spindle 
formation, (120) while loss of N-terminal methylation of 
the DNA repair protein DNA-binding protein 2 (DDB2) impairs 
its recruitment to damaged DNA, and subsequently, 
nucleotide excision repair (NER) (52). 
My work focuses on the homologous N-terminal 
methyltransferases NRMT1 (N-terminal RCC1 methyltransferase 
1) and NRMT2 (N-terminal RCC1 methyltransferase 2).  
Following cleavage of the initiating methionine, they 
methylate the α-amine of the first N-terminal residue of 
their targets (46,128).  They differ in catalytic 
specificity in that NRMT2 is a monomethylase, and NRMT1 is 
a trimethylase (46,128).  NRMT1 is a distributive 
trimethylase, as it binds its substrate and adds one methyl 
group at a time, dissociating from the substrate after the 
addition of each methyl group (46).  NRMT2 primes 
substrates with the first methyl group, thereby increasing 
trimethylation rates of NRMT1 (46).  NRMT1 and NRMT2 are 
50% identical and 75% similar and share an N-terminal X-P-K 
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consensus sequence (44,46).  Based on this consensus 
sequence, it is predicted that these methyltransferases 
target over 300 substrates in humans (44). 
Y641 of EZH2 aligns with similar tyrosines in the 
active sites of other methyltransferases, including G9a and 
SETD7, and confers trimethylase activity to both these 
methyltransferases when mutated to phenylalanine or alanine 
(62,107).  The corresponding aromatic residues in NRMT1 and 
NRMT2 are Y19 and F75, respectively (46).  Given that 
mutation of tyrosine to phenylalanine has been shown to 
change catalytic specificity, (105) I hypothesized these 
aromatic residues were responsible for the differing 
catalytic activities of NRMT1 and NRMT2.  In addition to 
Y19 and F75, the active sites of NRMT1 and NRMT2 have 
differing aromatic residues at positions W20 and Y76, 
respectively (46).  I also tested the effect of these 
residues on the catalytic specificities of NRMT1 and NRMT2. 
Lastly, both NRMT1 and NRMT2 mutations are found in 
human cancers (Cosmic Catalogue of Somatic Mutations in 
Cancer; 
http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/).  
While mutations of Y19 or F75 have yet to be identified, I 
tested whether other mutations nearby (NRMT1 Q144H - lung 
cancer) or in the adjacent peptide-binding channel (NRMT1 
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N209I - endometrial cancer; NRMT1 P211S - lung cancer; and 
NRMT2 V224L - breast cancer) alter catalytic activity 
(Cosmic Catalogue of Somatic Mutations in Cancer). 
It has been shown that loss of NRMT1 results in 
oncogenic phenotypes such as increased proliferation, cell 
invasion and migration, and an increased sensitivity to DNA 
damaging agents (50,51).  These phenotypes suggest that 
methylation by NRMT2 alone is insufficient to functionally 
compensate for the loss of trimethylation, (50,51) and 
indicates a decrease in NRMT1 trimethylase activity will 
result in similar oncogenic phenotypes.  Determining which 
cancer mutations alter the levels of N-terminal methylation 
can help to determine their role in promoting tumor 
progression and also provide a marker for tumors more 
sensitive to DNA damaging agents.  Studying mutations in 
the conserved aromatic residues of the active site will 
also tell us whether these residues can universally control 
catalytic specificity or if alternate structural motifs 
contribute to the catalytic specificity of NRMT1 and NRMT2. 
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MATERIALS AND METHODS 
 
Constructs and Antibodies 
 
To make His6-tagged recombinant protein, the human 
NRMT1 and NRMT2 ORFs (GE Dharmacon, Marlborough, MA) were 
amplified to introduce a 5’ NdeI restriction site and a 3’ 
XhoI restriction site, and subcloned into pET15b vector 
(EMD Millipore, Billerica, MA).  These were used as 
templates for constructing all subsequent NRMT1 and NRMT2 
mutants using the Quikchange site-directed mutagenesis 
protocol (Agilent Technologies, Santa Clara, CA).  The 
following forward primers and their reverse complements 
were used: 
Y19F: 5’-CCAAGGCCAAGACCTTCTGGAAACAAATCCCAC-3’  







All His6 proteins were purified as previously described 
(129). 
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 Primary antibodies used for western blots are as 
follows: 1:5000 polyclonal rabbit anti-me1/2RCC1 (mono-
/dimethylated SPK-RCC1) (120), 1:10,000 polyclonal rabbit 
anti-me3RCC1 (trimethylated SPK-RCC1) (120), 1:1000 
polyclonal goat anti-RCC1 (Santa Cruz Biotechnology, sc-
1162, Santa Cruz, CA), 1:2000 polyclonal rabbit anti-NRMT1 
(128), 1:3000 polyclonal rabbit anti-GAPDH (Trevigen, 
Gaithersburg, MD), and 1:1000 monoclonal mouse anti-
polyHistidine (Sigma Aldrich, St. Louis, MO). 1:1000 
polyclonal rabbit anti-Mettl11a/NRMT1 (Abcam, Cambridge, 
United Kingdom) was used to detect WT and mutant NRMT1 
(Fig. 9) as the NRMT1 antibody created by the lab 
recognizes an epitope containing N209 and P211.  Secondary 
donkey anti-rabbit, anti-mouse, and anti-goat HRP 
antibodies were used.  For western blots, 10% 
polyacrylamide gels and tris-glycine separation were used; 
proteins were transferred to nitrocellulose membranes, 
which were blocked using 5% nonfat dry milk in TBST (200 mM 
Tris, 1.37 M NaCl, 0.05% Tween-20; pH 7.5). 
 
In Vitro Methylation Assays 
 
All methylation assays were conducted at 30 °C using 1 μg recombinant enzyme (full-length protein), 0.5 μg 
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recombinant RCC1 substrate (full-length protein), and 100 μM 
AdoMet unless otherwise noted.  The reaction volume was 
adjusted to 50 μl with methyltransferase buffer (50 mM 
potassium acetate, 50 mM Tris/HCl, pH 8), and reactions 
were run for one hour.  Methylation assays using varied 
RCC1 concentration were conducted using 1 μg recombinant 
enzyme, 0.1-2 μg recombinant RCC1 substrate, and 100 μM 
AdoMet.  The reaction volume and time were unchanged.  
Methylation assays conducted at varying times used 1 μg 
recombinant enzyme, 0.5 μg recombinant RCC1 substrate, and 
100 μM AdoMet.  The reaction volume was unchanged, but 
reactions were run for 30 minutes to 3 hours.  Methylation 
assays were visualized by western blot analysis, except for 
mass spectrometry samples.  Samples were prepared for MS 
analysis by performing a methyltransferase assay using 1 μg 
recombinant enzyme, 0.5 μg recombinant RCC1 substrate, and 
100 μM AdoMet.  Reaction volume was adjusted to 20 μl with 
methyltransferase buffer, and reactions were run for one 
hour at 30 °C.  Reactions were run on an SDS/PAGE gel, and 
bands visualized by Coomassie Blue stain.  The analysis for 
the presence and extent of RCC1 N-terminal methylation by 






A549 human lung carcinoma cells (ATCC) were maintained 
in Dulbecco’s Modified Eagle Medium (DMEM) (Life 
Technologies, Grand Island, NY) with 10% fetal bovine serum 
(FBS) (Atlanta Biologicals, Atlanta, GA) and 1% penicillin-
streptomycin (P/S) (Life Technologies).  HCT116 human 
colorectal carcinoma cells lines (a generous gift from Dr. 
Ian Macara, Vanderbilt University) were maintained in 
McCoy’s 5a Modified Medium with 10% FBS and 1% P/S.  
HEK293LT human embryonic kidney cells (also a generous gift 
from Dr. Ian Macara) were grown in DMEM with 10% FBS and 1% 
P/S. 
 
Generation of NRMT1 CRISPR/Cas9 Knockout Cell Line 
 
Suitable CRISPR/Cas9 target sites in the human NRMT1 
gene were identified using an online CRISPR Design Tool 
(http://tools.genome-engineering.org) (130).  A target site 
in the first exon (Fig. 10) was chosen and the following 
oligos designed and ordered from Integrated DNA 
Technologies (IDT, Coralville, IA). 
Top: 5’- CACCGACGGTGGACGGCATGCTTGG - 3’ 
Bottom: 5’- AAACCCAAGCATGCCGTCCACCGTC- 3’ 
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The oligos were annealed, phosphorylated, and subcloned 
into BbsI-digested pSpCas9(BB)-2A-Puro (Addgene, Cambridge, 
MA) as previously described (130).  Resulting clones were 
verified by DNA sequencing.  6 x 105 HCT116 cells were 
transfected with 250 ng either empty pSpCas9(BB)-2A-Puro or 
the same vector containing the NRMT1 target sequence.  48 
hours post-transfections, cells were treated with 2 µg/ml 
puromycin for three days.  Surviving cells were transferred 
to individual wells in a 96-well plate.  Cells were 
expanded and passaged.  Half were used to make carry plates 
the other half were used to isolate genomic DNA.  For the 
first six wells, the genomic DNA was PCR amplified with 
primers flanking the target sequence.  The resultant PCR 
products were sequenced at the University of Louisville 
Genomics Core.  All six clones contained frameshift 
mutations and were selected for expansion, and analyzed for 
NRMT1 expression and N-terminal methylation by western blot 





Wild type (WT), N209I, or P211S human NRMT1 were 
amplified from the pet15b vector to introduce a 5’ PmeI 
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restriction site and a 3’ PmeI restriction site, and 
subcloned into pWPI lentiviral expression vector (Addgene).  
GFP-tagged lentivirus expressing WT NRMT1, N209I NRMT1, or 
P211S NRMT1 were made by co-transfecting HEK293LT cells 
with 50 µg pWPI containing the appropriate NRMT1 cDNA, 37.5 
µg psPAX2 packaging vector, and 15 µg pMD2.G envelope 
plasmid using calcium phosphate transfection.  48 hours 
post-transfection, viral supernatants were collected, 
concentrated with 100K ultrafilters (EMD Millipore), and 
titered in the HEK293LT cells.  A549, HCT116, or HCT116 
NRMT1 KO cells were infected with virus to a multiplicity 
of infection (MOI) of 1.  Calculations performed to 
estimate MOI are based on the detection of GFP-positive 
cells by microscopy, and the dilution of virus necessary to 
achieve this.  Three days post-transduction, cells were 
counted and used in cell growth assays; remaining cells 
were used for western blot analysis. 
 
Cell Growth Assays 
 
One thousand control A549, HCT116, HCT116 NRMT1 KO, or 
HCT116 pSpCas9 cells were plated in triplicate in a 96-well 
plate in 100 µl of the appropriate cell culture media.  
Concurrently, A549, HCT116, or HCT116 NRMT1 KO cells 
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transduced with WT, N209I, or P211S NRMT1-expressing virus 
were plated in triplicate in 96-well plates.  Five sets of 
triplicates for each condition were made.  On the day of 
plating (day 0), 20 µl of Aqueous One Solution (Promega, 
Madison, WI) (CellTiter 96â AQueous One Solution Cell 
Proliferation Assay) was added to the first set of 
triplicates for each condition and the absorbance at 490 nm 
was read after two hours.  Readings were taken on day 0 and 
daily for four additional days.  Relative fold increase was 
calculated by dividing average absorbance on each day by 





Aromatic Cage Mutants Do Not Exhibit Altered Methylation 
Patterns 
 
Y19 is the NRMT1 tyrosine residue that most closely 
aligns with the position of Y641 in the methyltransferase 
active site of EZH2.  In NRMT2, this residue is replaced by 
F75.  As mutation of EZH2 Y641 to phenylalanine switches 
its catalytic activity, I hypothesized this amino acid 
substitution between NRMT1 and NRMT2 might be the cause of 
their differing catalytic activities.  To test this 
hypothesis, recombinant proteins were made for NRMT1 Y19F 
and NRMT2 F75Y, and their ability to mono-, di-, or 
trimethylate full-length recombinant RCC1 over one hour was 
assayed by western blot.  Unexpectedly, neither mutation 
significantly affected methyltransferase activity (Fig. 
2A,B; Fig. 3A,B).  Similar to wild type (WT) NRMT1, NRMT1 
Y19F exhibited only trimethylase activity (Fig. 2A,B).  
Similar to WT NRMT2, NRMT2 F75Y exhibited only 
monomethylase activity (Fig. 3A,B).  
In addition to an inability to switch catalytic 
activities, these mutations also did not significantly 






































































































































































Figure 2. N-terminal methylation patterns of wild type and 
mutant NRMT1. 
The directed mutation of aromatic residues Y19 and W20 in 
NRMT1 and the Q144H mutation found in human lung cancer 
showed no effects on (A) monomethylation/dimethylation 
(me1/2RCC1) or (B) trimethylation (me3RCC1) levels.  
However, the NRMT1 mutants N209I (endometrial cancer) and 
P211S (lung cancer) exhibit (A) increased 
monomethylation/dimethylation of RCC1 and (B) decreased 
trimethylation of RCC1 as compared to wild type (WT).  
Total RCC1 is shown as loading control.  (C) Densitometry 
analysis of panel A.  Ratio of me1/2RCC1:Total RCC1 band 
intensity.  (D) Densitometry analysis of panel B.  Ratio of 
me3RCC1:Total RCC1 band intensity, normalized to WT NRMT1.  
Each data point represents the ± SEM of three independent 
experiments.  * denotes P < 0.05, determined by an unpaired 
two-tailed Student’s t-test.  Bands were quantified using 
































































































































Figure 3. N-terminal methylation patterns of wild type and 
mutant NRMT2. 
The directed mutation of aromatic residues F75 and Y76 in 
NRMT2 showed no effect on (A) mono-/dimethylase activity 
(B) but no corresponding increase in trimethylase activity.  
The breast cancer mutation of V224 in NRMT2 showed a 
significant decrease in (A) mono-/dimethylase activity (B) 
but no corresponding increase in trimethylase activity.    
Total RCC1 is shown as loading control.  (C) Densitometry 
analysis of panel A.  Ratio of me1/2RCC1:Total RCC1 band 
intensity, normalized to WT NRMT2.  (D) Densitometry 
analysis of panel B.  Ratio of me3RCC1:Total RCC1 band 
intensity, normalized to WT NRMT1.  As previously shown, 
trimethylation levels are significantly different between 
WT NRMT1 and WT NRMT2 (46), but none of the NRMT2 mutants 
were significantly different from WT NRMT2.  Low levels of 
trimethylation signal seen with WT NRMT2 are not due to 
trimethylation activity but cross-reactivity of me3RCC1 
antibody with lower levels of methylation when no 
trimethylation is present (46,47).  Each data point 
represents the mean ± SEM of three independent experiments.  
* denotes P < 0.05, determined by an unpaired two-tailed 
Student’s t-test.  Bands were quantified using ImageJ 
software (NIH).  
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is contrary to published data showing that the NRMT1 Y19F 
mutation significantly inhibits the ability of WT 
recombinant NRMT1 to methylate an N-terminal peptide of  
CENP-A (131).  As my assay was done with full-length 
recombinant RCC1 as substrate, it may be that 
enzyme/substrate binding is enhanced by interactions with 
the full protein and the interaction of Y19 with substrate 
is more imperative for peptide substrates.  It may also be 
consensus sequence dependent.  The CENP-A N-terminal 
sequence is Gly-Pro-Arg (GPR), while the RCC1 N-terminal 
sequence is Ser-Pro-Lys (SPK).  The recently solved crystal 
structure of human NRMT1 bound to CENP-A N-terminal peptide 
indicates the Arg residue in the CENP-A consensus sequence 
forms hydrogen bonds and electrostatic interactions with 
Y19 (131).  These interactions may differ with a lysine 
residue and make Y19 less crucial for catalytic function. 
As the mutations in Y19 and F75 did not significantly 
alter the methyltransferase activities of NRMT1 and NRMT2, 
I next mutated the other aromatic residue that differs 
between their active sites.  W20 in NRMT1 is replaced with 
Y76 in NRMT2 (46).  Full-length recombinant proteins were 
made for NRMT1 W20Y and NRMT2 Y76W, and their ability to 
mono-, di-, or trimethylate full-length recombinant RCC1 
was assayed by western blot.  Again, neither mutation 
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significantly affected methyltransferase activity (Fig. 
2A,B; Fig. 3A,B).  This is also contrary to previous 
published data showing the W20Y mutation of NRMT1 
significantly diminishes its ability to methylate the N-
terminal peptide of CENP-A, (131) and further indicates the 
most important catalytic residues may differ depending on 
substrate length or consensus sequence. 
To differentiate between these two possibilities, site 
directed mutagenesis was performed on the plasmid used to 
make full-length recombinant RCC1.  GPR-RCC1 was made to 
mimic the CENP-A consensus sequence on a full-length 
protein, as well as Gly-Pro-Lys (GPK) and Ser-Pro-Arg 
(SPR)-RCC1 to assess if the first or third amino acid is 
more important.  Wild type SPK-RCC1, as well as all three 
full-length RCC1 consensus sequence mutants (GPK, SPR, and 
GPR) could be in vitro methylated by WT, Y19F, and W20Y 
NRMT1 (Fig. 4 A-D), indicating that the impaired Y19F and 
W20Y activity seen by Wu et al. (110) is not due to a 
difference in the three amino acid consensus sequence. 
To determine if the impaired activity resulted from 
substrate length, the activity of Y19F and W20Y NRMT1 on a 
peptide containing the first 15 amino acids of WT RCC1 

















































































































Supplemental Fig. 1. Y19F and W20Y NRMT1 activity is not altered by changing the RCC1 consensus
sequence, but W20Y activity is lost when using peptide substrate.  (A) Western blots showing wild type (WT), 
Y19F, and W20Y NRMT1 all trimethylate WT (SPK) full-length recombinant RCC1 (me3RCC1).  Mutation of 
the RCC1 consensus sequence to (B) SPR, (C) GPK, or (D) GPR does not affect the ability of WT, Y19F, or 
W20Y to trimethylate the full-length substrate.  NRMT1 blots shown to confirm equal loading of enzyme. 
(E) Dot blot showing W20Y trimethyl (me3RCC1) and mono/dimethyl (me1/2RCC1) activity is lost when the
substrate is switched to a wild type (SPK) RCC1 N-terminal peptide. Tri- or monomethylated RCC1 peptide is 
































Figure 4. Y19F and W20Y NRMT1 activity is not altered by 
changing the RCC1 consensus sequence, but W20Y activity is 
lost when using peptide substrate. 
(A) Western blots showing wild type (WT), Y19F, and W20Y 
NRMT1 all trimethylate WT (SPK) full-length recombinant 
RCC1 (me3RCC1).  Mutation of the RCC1 consensus sequence to 
(B) SPR, (C) GPK, or (D) GPR does not affect the ability of 
WT, Y19F, or W20Y to trimethylate the full-length 
substrate.  NRMT1 blots shown to confirm equal loading of 
enzyme.  (E) Dot blot showing W20Y trimethyl (me3RCC1) and 
mono-/dimethyl (me1/2RCC1) activity is lost when the 
substrate is switched to a wild type (SPK) RCC1 N-terminal 
peptide.  Tri- or monomethylated RCC1 peptide is shown as a 
positive control (Control).  Blots are representative 
images of three independent experiments.  Work in this 
figure was performed by John Tooley, State University of 
New York at Buffalo. 
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Interestingly, Y19F was still able to trimethylate the 
peptide, while W20Y was not (Fig. 4E), indicating it is 
possible for a recombinant enzyme to have different 
activities towards full-length and peptide substrates with 
the same consensus  
sequence. 
 
Mutations Found in Human Cancers Alter NRMT1 and NRMT2 
Activities 
 
Human cancer mutations of NRMT1 and NRMT2 were selected 
from the Cosmic Catalogue of Somatic Mutations in Cancer 
database based on their proximity to the active site or 
peptide-binding channel.  For NRMT1, I selected Q144H (lung 
cancer), N209I (endometrial cancer), and P211S (lung 
cancer).  Both the N209I and P211S mutations are in the 
peptide binding channel of NRMT1, (131) while the Q144H 
mutation is adjacent to H140, a third aromatic residue in 
the active site (46).  Unlike Y19 and W20, this histidine 
is conserved between NRMT1 and NRMT2 (46).  For NRMT2, I 
selected V224L (breast cancer).  This valine is analogous 
to M169 in NRMT1, (46) which is directly adjacent to N168, 
an amino acid that forms both hydrogen bonds and 
electrostatic interactions with substrate (131,132). 
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In vitro methylation assays with the full-length 
recombinant mutants and full-length recombinant RCC1 as a 
substrate, showed the Q144H lung cancer mutation exhibited 
similar levels of mono-/dimethylation (Fig. 2A) and 
trimethylation (Fig. 2B) as WT NRMT1.  In contrast, the 
N209I endometrial and P211S lung cancer mutants displayed 
significantly increased levels of mono-/dimethylation (Fig. 
2A,C) and significantly decreased levels of trimethylation 
(Fig. 2B,D) compared to WT NRMT1, indicating these 
mutations in patients could decrease global N-terminal 
methylation levels in favor of mono-/dimethylation.  As 
seen with WT NRMT2, the NRMT2 V224L breast cancer mutation 
exhibited no trimethylase activity (Fig. 3B), but it also 
exhibited significantly decreased monomethylase activity as 
compared to control (Fig. 3A and C).  This indicates 
patients harboring this mutation would have lower levels of 
priming activity by NRMT2 and potentially less 
trimethylation by NRMT1 as a consequence (46). 
 
Mass Spectrometry Verification of N209I and P211S Shifted 
Methylation Activity 
 
 As the N-terminal mono-/dimethyl RCC1 antibody 
(me1/2RCC1) that was created cannot discriminate between 
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mono- and dimethylation, mass spectrometry (MS) analysis 
was used to determine if the N209I and P211S NRMT1 mutants 
were capable of monomethylation, dimethylation, or both.  
The results from the MS analysis (Fig. 5, Fig. 6A-J) showed 
that, of the recombinant RCC1 that underwent successful  
cleavage of the initiating methionine (a portion of 
recombinant RCC1 fails to undergo this cleavage and is 
unable to be methylated in vitro), 63% was trimethylated by 
WT NRMT1 and the remaining 37% remained unmethylated (46).  
This is consistent with previous results showing WT NRMT1 
will almost completely trimethylate RCC1 after one hour in 
vitro (46). 
 With the N209I mutation, unmethylated RCC1 levels 
increased to 73%, while RCC1 trimethylation levels dropped 
to 13%, dimethylation levels increased to 7% and 
monomethylation levels increased to 6%.  With the P211S 
mutant, unmethylated RCC1 levels also increased to 73%, 
trimethylation was further decreased to 5%, dimethylation 
increased to 13%, and monomethylation increased to 9%.  The 
MS analysis is consistent with the western blot results, 
indicating these mutants exhibit decreased trimethylase  
activity and increased mono- and dimethylase activity.  
They also indicate, that unlike the EZH2 mutants which 
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Figure 5. Mass spectrometry analysis of WT and mutant 
NRMT1. 
Of the recombinant RCC1 with cleavage of the initiating 
methionine, 63% was N-terminally trimethylated by 
recombinant WT NRMT1. The remaining 37% remained 
unmethylated. With the N209I mutation, unmethylated RCC1 
levels increased to 73%, while RCC1 trimethylation levels 
dropped to 13%, dimethylation levels increased to 7%, and 
monomethylation levels increased to 6%. With the P211S 
mutant, unmethylated RCC1 levels also increased to 73%, 
trimethylation was further decreased to 5%, dimethylation 
increased to 13%, and monomethylation increased to 9%.  I 
prepared the graph contained in this figure, but the mass 
spectrometry analysis was performed by the University of 
Louisville Mass Spectrometry Core Laboratory and represents 











































     Extracted from: D:\Data\C.SchanerTooley\150428_SchanerTooley\WT_SchanerTooley_150428.raw   #746   RT: 12.78
     ITMS, ETD@44.00, z=+3, Mono m/z=488.63516 Da, MH+=1463.89093 Da, Match Tol.=1.2 Da
#1# c⁺# c²⁺# Seq.# y⁺# y²⁺# z⁺# z²⁺# z+2⁺# z+2²⁺# #2#
1 105.06586 53.03657 S       13 
2 202.11863 101.56295 P 1376.85979 688.93353 1360.84107 680.92417 1362.85672 681.93200 12 
3 330.21360 165.61044 K 1279.80702 640.40715 1263.78830 632.39779 1265.80395 633.40561 11 
4 486.31472 243.66100 R 1151.71205 576.35966 1135.69333 568.35030 1137.70898 569.35813 10 
5 599.39879 300.20303 I 995.61093 498.30910 979.59221 490.29974 981.60786 491.30757 9 
6 670.43591 335.72159 A 882.52686 441.76707 866.50814 433.75771 868.52379 434.76553 8 
7 798.53088 399.76908 K 811.48974 406.24851 795.47102 398.23915 797.48667 399.24697 7 
8 954.63200 477.81964 R 683.39477 342.20102 667.37605 334.19166 669.39170 335.19949 6 
9 1110.73312 555.87020 R 527.29365 264.15046 511.27493 256.14110 513.29058 257.14893 5 
10 1197.76515 599.38621 S 371.19253 186.09990 355.17381 178.09054 357.18946 179.09837 4 
11 1294.81792 647.91260 P 284.16050 142.58389 268.14178 134.57453 270.15743 135.58235 3 
12 1391.87069 696.43898 P 187.10773 94.05750 171.08901 86.04814 173.10466 87.05597 2 














































     Extracted from: D:\Data\C.SchanerTooley\150428_SchanerTooley\WT_SchanerTooley_150428.raw   #1450   RT: 20.93
     ITMS, ETD@33.00, z=+4, Mono m/z=377.24014 Da, MH+=1505.93874 Da, Match Tol.=1.2 Da
#1# c⁺# c²⁺# c³⁺# Seq.# y⁺# y²⁺# y³⁺# z⁺# z²⁺# z³⁺# z+2⁺# z+2²⁺# z+2³⁺# #2#
1 147.11281 74.06004 49.70912 S-Trimethyl          13 
2 244.16558 122.58643 82.06004 P 1376.85979 688.93353 459.62478 1360.84107 680.92417 454.28521 1362.85672 681.93200 454.95709 12 
3 372.26055 186.63391 124.75837 K 1279.80702 640.40715 427.27386 1263.78830 632.39779 421.93428 1265.80395 633.40561 422.60617 11 
4 528.36167 264.68447 176.79207 R 1151.71205 576.35966 384.57553 1135.69333 568.35030 379.23596 1137.70898 569.35813 379.90784 10 
5 641.44574 321.22651 214.48676 I 995.61093 498.30910 332.54183 979.59221 490.29974 327.20225 981.60786 491.30757 327.87414 9 
6 712.48286 356.74507 238.16580 A 882.52686 441.76707 294.84714 866.50814 433.75771 289.50756 868.52379 434.76553 290.17945 8 
7 840.57783 420.79255 280.86413 K 811.48974 406.24851 271.16810 795.47102 398.23915 265.82852 797.48667 399.24697 266.50041 7 
8 996.67895 498.84311 332.89783 R 683.39477 342.20102 228.46977 667.37605 334.19166 223.13020 669.39170 335.19949 223.80208 6 
9 1152.78007 576.89367 384.93154 R 527.29365 264.15046 176.43607 511.27493 256.14110 171.09649 513.29058 257.14893 171.76838 5 
10 1239.81210 620.40969 413.94222 S 371.19253 186.09990 124.40236 355.17381 178.09054 119.06279 357.18946 179.09837 119.73467 4 
11 1336.86487 668.93607 446.29314 P 284.16050 142.58389 95.39168 268.14178 134.57453 90.05211 270.15743 135.58235 90.72399 3 
12 1433.91764 717.46246 478.64406 P 187.10773 94.05750 63.04076 171.08901 86.04814 57.70119 173.10466 87.05597 58.37307 2 















































     Extracted from: D:\Data\C.SchanerTooley\150428_SchanerTooley\N209I_SchanerTooley_150428.raw   #731   RT: 12.01
     ITMS, ETD@44.00, z=+3, Mono m/z=488.63538 Da, MH+=1463.89157 Da, Match Tol.=1.2 Da
#1# c⁺# c²⁺# Seq.# y⁺# y²⁺# z⁺# z²⁺# z+2⁺# z+2²⁺# #2#
1 105.06586 53.03657 S       13 
2 202.11863 101.56295 P 1376.85979 688.93353 1360.84107 680.92417 1362.85672 681.93200 12 
3 330.21360 165.61044 K 1279.80702 640.40715 1263.78830 632.39779 1265.80395 633.40561 11 
4 486.31472 243.66100 R 1151.71205 576.35966 1135.69333 568.35030 1137.70898 569.35813 10 
5 599.39879 300.20303 I 995.61093 498.30910 979.59221 490.29974 981.60786 491.30757 9 
6 670.43591 335.72159 A 882.52686 441.76707 866.50814 433.75771 868.52379 434.76553 8 
7 798.53088 399.76908 K 811.48974 406.24851 795.47102 398.23915 797.48667 399.24697 7 
8 954.63200 477.81964 R 683.39477 342.20102 667.37605 334.19166 669.39170 335.19949 6 
9 1110.73312 555.87020 R 527.29365 264.15046 511.27493 256.14110 513.29058 257.14893 5 
10 1197.76515 599.38621 S 371.19253 186.09990 355.17381 178.09054 357.18946 179.09837 4 
11 1294.81792 647.91260 P 284.16050 142.58389 268.14178 134.57453 270.15743 135.58235 3 
12 1391.87069 696.43898 P 187.10773 94.05750 171.08901 86.04814 173.10466 87.05597 2 











































     Extracted from: D:\Data\C.SchanerTooley\150428_SchanerTooley\N209I_SchanerTooley_150428.raw   #577   RT: 10.16
     ITMS, ETD@33.00, z=+4, Mono m/z=370.23248 Da, MH+=1477.90810 Da, Match Tol.=1.2 Da
#1# c⁺# c²⁺# c³⁺# Seq.# y⁺# y²⁺# y³⁺# z⁺# z²⁺# z³⁺# z+2⁺# z+2²⁺# z+2³⁺# #2#
1 119.08151 60.04439 40.36535 S-Methyl          13 
2 216.13428 108.57078 72.71628 P 1376.85979 688.93353 459.62478 1360.84107 680.92417 454.28521 1362.85672 681.93200 454.95709 12 
3 344.22925 172.61826 115.41460 K 1279.80702 640.40715 427.27386 1263.78830 632.39779 421.93428 1265.80395 633.40561 422.60617 11 
4 500.33037 250.66882 167.44831 R 1151.71205 576.35966 384.57553 1135.69333 568.35030 379.23596 1137.70898 569.35813 379.90784 10 
5 613.41444 307.21086 205.14300 I 995.61093 498.30910 332.54183 979.59221 490.29974 327.20225 981.60786 491.30757 327.87414 9 
6 684.45156 342.72942 228.82204 A 882.52686 441.76707 294.84714 866.50814 433.75771 289.50756 868.52379 434.76553 290.17945 8 
7 812.54653 406.77690 271.52036 K 811.48974 406.24851 271.16810 795.47102 398.23915 265.82852 797.48667 399.24697 266.50041 7 
8 968.64765 484.82746 323.55407 R 683.39477 342.20102 228.46977 667.37605 334.19166 223.13020 669.39170 335.19949 223.80208 6 
9 1124.74877 562.87802 375.58777 R 527.29365 264.15046 176.43607 511.27493 256.14110 171.09649 513.29058 257.14893 171.76838 5 
10 1211.78080 606.39404 404.59845 S 371.19253 186.09990 124.40236 355.17381 178.09054 119.06279 357.18946 179.09837 119.73467 4 
11 1308.83357 654.92042 436.94937 P 284.16050 142.58389 95.39168 268.14178 134.57453 90.05211 270.15743 135.58235 90.72399 3 
12 1405.88634 703.44681 469.30030 P 187.10773 94.05750 63.04076 171.08901 86.04814 57.70119 173.10466 87.05597 58.37307 2 

















































     Extracted from: D:\Data\C.SchanerTooley\150428_SchanerTooley\N209I_SchanerTooley_150428.raw   #726   RT: 11.95
     ITMS, ETD@44.00, z=+3, Mono m/z=497.96649 Da, MH+=1491.88492 Da, Match Tol.=1.2 a
#1# c⁺# c²⁺# Seq.# y⁺# y²⁺# z⁺# z²⁺# z+2⁺# z+2²⁺# #2#
1 133.09716 67.05222 S-Dimethyl       13 
2 230.14993 115.57860 P 1376.85979 688.93353 1360.84107 680.92417 1362.85672 681.93200 12 
3 358.24490 179.62609 K 1279.80702 640.40715 1263.78830 632.39779 1265.80395 633.40561 11 
4 514.34602 257.67665 R 1151.71205 576.35966 1135.69333 568.35030 1137.70898 569.35813 10 
5 627.43009 314.21868 I 995.61093 498.30910 979.59221 490.29974 981.60786 491.30757 9 
6 698.46721 349.73724 A 882.52686 441.76707 866.50814 433.75771 868.52379 434.76553 8 
7 826.56218 413.78473 K 811.48974 406.24851 795.47102 398.23915 797.48667 399.24697 7 
8 982.66330 491.83529 R 683.39477 342.20102 667.37605 334.19166 669.39170 335.19949 6 
9 1138.76442 569.88585 R 527.29365 264.15046 511.27493 256.14110 513.29058 257.14893 5 
10 1225.79645 613.40186 S 371.19253 186.09990 355.17381 178.09054 357.18946 179.09837 4 
11 1322.84922 661.92825 P 284.16050 142.58389 268.14178 134.57453 270.15743 135.58235 3 
12 1419.90199 710.45463 P 187.10773 94.05750 171.08901 86.04814 173.10466 87.05597 2 


































     Extracted from: D:\Data\C.SchanerTooley\150428_SchanerTooley\N209I_SchanerTooley_150428.raw   #712   RT: 11.82
     ITMS, ETD@33.00, z=+4, Mono m/z=377.23114 Da, MH+=1505.90273 Da, Match Tol.=1.2 Da
#1# c⁺# c²⁺# c³⁺# Seq.# y⁺# y²⁺# y³⁺# z⁺# z²⁺# z³⁺# z+2⁺# z+2²⁺# z+2³⁺# #2#
1 147.11281 74.06004 49.70912 S-Trimethyl          13 
2 244.16558 122.58643 82.06004 P 1376.85979 688.93353 459.62478 1360.84107 680.92417 454.28521 1362.85672 681.93200 454.95709 12 
3 372.26055 186.63391 124.75837 K 1279.80702 640.40715 427.27386 1263.78830 632.39779 421.93428 1265.80395 633.40561 422.60617 11 
4 528.36167 264.68447 176.79207 R 1151.71205 576.35966 384.57553 1135.69333 568.35030 379.23596 1137.70898 569.35813 379.90784 10 
5 641.44574 321.22651 214.48676 I 995.61093 498.30910 332.54183 979.59221 490.29974 327.20225 981.60786 491.30757 327.87414 9 
6 712.48286 356.74507 238.16580 A 882.52686 441.76707 294.84714 866.50814 433.75771 289.50756 868.52379 434.76553 290.17945 8 
7 840.57783 420.79255 280.86413 K 811.48974 406.24851 271.16810 795.47102 398.23915 265.82852 797.48667 399.24697 266.50041 7 
8 996.67895 498.84311 332.89783 R 683.39477 342.20102 228.46977 667.37605 334.19166 223.13020 669.39170 335.19949 223.80208 6 
9 1152.78007 576.89367 384.93154 R 527.29365 264.15046 176.43607 511.27493 256.14110 171.09649 513.29058 257.14893 171.76838 5 
10 1239.81210 620.40969 413.94222 S 371.19253 186.09990 124.40236 355.17381 178.09054 119.06279 357.18946 179.09837 119.73467 4 
11 1336.86487 668.93607 446.29314 P 284.16050 142.58389 95.39168 268.14178 134.57453 90.05211 270.15743 135.58235 90.72399 3 
12 1433.91764 717.46246 478.64406 P 187.10773 94.05750 63.04076 171.08901 86.04814 57.70119 173.10466 87.05597 58.37307 2 












































     Extracted from: D:\Data\C.SchanerTooley\150428_SchanerTooley\P211S_SchanerTooley_150428.raw   #719   RT: 11.55
     ITMS, ETD@44.00, z=+3, Mono m/z=488.63657 Da, MH+=1463.89515 Da, Match Tol.=1.2 Da
#1# c⁺# c²⁺# Seq.# y⁺# y²⁺# z⁺# z²⁺# z+2⁺# z+2²⁺# #2#
1 105.06586 53.03657 S       13 
2 202.11863 101.56295 P 1376.85979 688.93353 1360.84107 680.92417 1362.85672 681.93200 12 
3 330.21360 165.61044 K 1279.80702 640.40715 1263.78830 632.39779 1265.80395 633.40561 11 
4 486.31472 243.66100 R 1151.71205 576.35966 1135.69333 568.35030 1137.70898 569.35813 10 
5 599.39879 300.20303 I 995.61093 498.30910 979.59221 490.29974 981.60786 491.30757 9 
6 670.43591 335.72159 A 882.52686 441.76707 866.50814 433.75771 868.52379 434.76553 8 
7 798.53088 399.76908 K 811.48974 406.24851 795.47102 398.23915 797.48667 399.24697 7 
8 954.63200 477.81964 R 683.39477 342.20102 667.37605 334.19166 669.39170 335.19949 6 
9 1110.73312 555.87020 R 527.29365 264.15046 511.27493 256.14110 513.29058 257.14893 5 
10 1197.76515 599.38621 S 371.19253 186.09990 355.17381 178.09054 357.18946 179.09837 4 
11 1294.81792 647.91260 P 284.16050 142.58389 268.14178 134.57453 270.15743 135.58235 3 
12 1391.87069 696.43898 P 187.10773 94.05750 171.08901 86.04814 173.10466 87.05597 2 

























































     Extracted from: D:\Data\C.SchanerTooley\150428_SchanerTooley\P211S_SchanerTooley_150428.raw   #617   RT: 10.16
     ITMS, ETD@33.00, z=+4, Mono m/z=370.23251 Da, MH+=1477.90822 Da, Match Tol.=1.2 Da
#1# c⁺# c²⁺# c³⁺# Seq.# y⁺# y²⁺# y³⁺# z⁺# z²⁺# z³⁺# z+2⁺# z+2²⁺# z+2³⁺# #2#
1 119.08151 60.04439 40.36535 S-Methyl          13 
2 216.13428 108.57078 72.71628 P 1376.85979 688.93353 459.62478 1360.84107 680.92417 454.28521 1362.85672 681.93200 454.95709 12 
3 344.22925 172.61826 115.41460 K 1279.80702 640.40715 427.27386 1263.78830 632.39779 421.93428 1265.80395 633.40561 422.60617 11 
4 500.33037 250.66882 167.44831 R 1151.71205 576.35966 384.57553 1135.69333 568.35030 379.23596 1137.70898 569.35813 379.90784 10 
5 613.41444 307.21086 205.14300 I 995.61093 498.30910 332.54183 979.59221 490.29974 327.20225 981.60786 491.30757 327.87414 9 
6 684.45156 342.72942 228.82204 A 882.52686 441.76707 294.84714 866.50814 433.75771 289.50756 868.52379 434.76553 290.17945 8 
7 812.54653 406.77690 271.52036 K 811.48974 406.24851 271.16810 795.47102 398.23915 265.82852 797.48667 399.24697 266.50041 7 
8 968.64765 484.82746 323.55407 R 683.39477 342.20102 228.46977 667.37605 334.19166 223.13020 669.39170 335.19949 223.80208 6 
9 1124.74877 562.87802 375.58777 R 527.29365 264.15046 176.43607 511.27493 256.14110 171.09649 513.29058 257.14893 171.76838 5 
10 1211.78080 606.39404 404.59845 S 371.19253 186.09990 124.40236 355.17381 178.09054 119.06279 357.18946 179.09837 119.73467 4 
11 1308.83357 654.92042 436.94937 P 284.16050 142.58389 95.39168 268.14178 134.57453 90.05211 270.15743 135.58235 90.72399 3 
12 1405.88634 703.44681 469.30030 P 187.10773 94.05750 63.04076 171.08901 86.04814 57.70119 173.10466 87.05597 58.37307 2 


















































     Extracted from: D:\Data\C.SchanerTooley\150428_SchanerTooley\P211S_SchanerTooley_150428.raw   #615   RT: 10.14
     ITMS, ETD@33.00, z=+4, Mono m/z=373.73621 Da, MH+=1491.92299 Da, Match Tol.=1.2 Da
#1# c⁺# c²⁺# c³⁺# Seq.# y⁺# y²⁺# y³⁺# z⁺# z²⁺# z³⁺# z+2⁺# z+2²⁺# z+2³⁺# #2#
1 133.09716 67.05222 45.03724 S-Dimethyl          13 
2 230.14993 115.57860 77.38816 P 1376.85979 688.93353 459.62478 1360.84107 680.92417 454.28521 1362.85672 681.93200 454.95709 12 
3 358.24490 179.62609 120.08648 K 1279.80702 640.40715 427.27386 1263.78830 632.39779 421.93428 1265.80395 633.40561 422.60617 11 
4 514.34602 257.67665 172.12019 R 1151.71205 576.35966 384.57553 1135.69333 568.35030 379.23596 1137.70898 569.35813 379.90784 10 
5 627.43009 314.21868 209.81488 I 995.61093 498.30910 332.54183 979.59221 490.29974 327.20225 981.60786 491.30757 327.87414 9 
6 698.46721 349.73724 233.49392 A 882.52686 441.76707 294.84714 866.50814 433.75771 289.50756 868.52379 434.76553 290.17945 8 
7 826.56218 413.78473 276.19224 K 811.48974 406.24851 271.16810 795.47102 398.23915 265.82852 797.48667 399.24697 266.50041 7 
8 982.66330 491.83529 328.22595 R 683.39477 342.20102 228.46977 667.37605 334.19166 223.13020 669.39170 335.19949 223.80208 6 
9 1138.76442 569.88585 380.25966 R 527.29365 264.15046 176.43607 511.27493 256.14110 171.09649 513.29058 257.14893 171.76838 5 
10 1225.79645 613.40186 409.27033 S 371.19253 186.09990 124.40236 355.17381 178.09054 119.06279 357.18946 179.09837 119.73467 4 
11 1322.84922 661.92825 441.62126 P 284.16050 142.58389 95.39168 268.14178 134.57453 90.05211 270.15743 135.58235 90.72399 3 
12 1419.90199 710.45463 473.97218 P 187.10773 94.05750 63.04076 171.08901 86.04814 57.70119 173.10466 87.05597 58.37307 2 



































     Extracted from: D:\Data\C.SchanerTooley\150428_SchanerTooley\P211S_SchanerTooley_150428.raw   #731   RT: 11.71
     ITMS, ETD@33.00, z=+4, Mono m/z=377.23132 Da, MH+=1505.90346 Da, Match Tol.=1.2 Da
#1# c⁺# c²⁺# c³⁺# Seq.# y⁺# y²⁺# y³⁺# z⁺# z²⁺# z³⁺# z+2⁺# z+2²⁺# z+2³⁺# #2#
1 147.11281 74.06004 49.70912 S-Trimethyl          13 
2 244.16558 122.58643 82.06004 P 1376.85979 688.93353 459.62478 1360.84107 680.92417 454.28521 1362.85672 681.93200 454.95709 12 
3 372.26055 186.63391 124.75837 K 1279.80702 640.40715 427.27386 1263.78830 632.39779 421.93428 1265.80395 633.40561 422.60617 11 
4 528.36167 264.68447 176.79207 R 1151.71205 576.35966 384.57553 1135.69333 568.35030 379.23596 1137.70898 569.35813 379.90784 10 
5 641.44574 321.22651 214.48676 I 995.61093 498.30910 332.54183 979.59221 490.29974 327.20225 981.60786 491.30757 327.87414 9 
6 712.48286 356.74507 238.16580 A 882.52686 441.76707 294.84714 866.50814 433.75771 289.50756 868.52379 434.76553 290.17945 8 
7 840.57783 420.79255 280.86413 K 811.48974 406.24851 271.16810 795.47102 398.23915 265.82852 797.48667 399.24697 266.50041 7 
8 996.67895 498.84311 332.89783 R 683.39477 342.20102 228.46977 667.37605 334.19166 223.13020 669.39170 335.19949 223.80208 6 
9 1152.78007 576.89367 384.93154 R 527.29365 264.15046 176.43607 511.27493 256.14110 171.09649 513.29058 257.14893 171.76838 5 
10 1239.81210 620.40969 413.94222 S 371.19253 186.09990 124.40236 355.17381 178.09054 119.06279 357.18946 179.09837 119.73467 4 
11 1336.86487 668.93607 446.29314 P 284.16050 142.58389 95.39168 268.14178 134.57453 90.05211 270.15743 135.58235 90.72399 3 
12 1433.91764 717.46246 478.64406 P 187.10773 94.05750 63.04076 171.08901 86.04814 57.70119 173.10466 87.05597 58.37307 2 
13    A 90.05496 45.53112 30.68984 74.03624 37.52176 25.35026 76.05189 38.52958 26.02215 1 
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Figure 6. ETD MS/MS spectra and sequence coverage of a-N-
terminal peptides from recombinant RCC1 methylated by WT 
NRMT1, N209I, or P211S. 
WT NRMT1 produced (A) 37% unmethylated and (B) 63% 
trimethylated RCC1.  N209I produced (C) 73% unmethylated, 
(D) 6% monomethylated, (E) 7% dimethylated, and (F) 13% 
trimethylated RCC1.  P211S produced (G) 73% unmethylated, 
(H) 9% monomethylated, (I) 13% dimethylated, and (J) 5% 
trimethylated RCC1.  All spectra were acquired and searched 
using Mascot (v1.30).  c ; y ; z ; z + 2 fragments were 
used for searching and the match tolerance was 1.2 Da.  
Bolded red indicates observed c-ion fragment.  Bolded blue 
indicates observed y- or z-ion fragment.  Raw data shown in 
this figure was generated by the University of Louisville 




a trimethylase, the NRMT1 mutations are decreasing the 
overall efficiency of the enzyme and preventing it from 
both converting unmodified substrate to monomethylated and 
monomethylated substrate to trimethylated. 
 
NRMT1 Cancer Mutants Remain Distributive Methyltransferases 
 
It was previously shown that NRMT1 works as a 
distributive enzyme, first monomethylating its substrate, 
then dissociating and reattaching for each subsequent 
methylation step (46).  Richardson et al. confirmed this 
distributive nature of NRMT1 and additionally showed it is 
working through a random sequential bi-bi mechanism (133).  
It was also shown that for the human RCC1 consensus 
sequence (Ser-Pro-Lys), affinity of NRMT1 for substrate 
increases with increasing substrate methylation levels, 
(46) and it was hypothesized that this helps the enzyme to 
quickly raise trimethylation levels without the 
accumulation of mono- or dimethylated substrate. 
In order to monitor if the N209I and P211S mutants were 
impaired in the conversion of mono-/dimethylation to 
trimethylation, I held enzyme and substrate concentrations 
constant and varied the time of the in vitro methylation 
reactions.  Western blot analysis showed that WT NRMT1, 
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even at just 30 minutes, converted all mono-/dimethylation 
to trimethylation (Fig. 7A).  While low levels of 
trimethylation can be seen at 30 minutes with both the 
N209I and P211S mutants, mono-/dimethylation levels are 
higher and stay steady (N209I) or continue to increase 
(P211S) up to 2 hours (Fig. 7B,C).  Finally, after 2 hours, 
mono-/dimethylation levels begin to decrease with a  
corresponding increase in trimethylation, indicating 
conversion of one to the other (Fig. 7B,C).  These data 
mirror the MS results (Fig. 5) and indicate that while 
N209I and P211S are still distributive enzymes capable of 
trimethylation, they are significantly slower at converting 
mono- and dimethylation into trimethylation. 
To assay whether the activity of the mutants could be 
restored by a significant increase in substrate 
concentration, I monitored the ability of the mutants to 
mono-/dimethylate or trimethylate RCC1 at varying substrate 
concentrations.  Western blot analysis of the in vitro 
methylation assays revealed that N209I and P211S require a 
higher substrate concentration to reach the trimethylation 
levels seen with WT (Fig. 7D-F).  At low substrate levels 
(0.25 µg), NRMT1 shows only trimethylated substrate (Fig. 
7D), while neither mutation exhibits any methyltransferase 
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Figure 7. Catalytic studies of WT and mutant NRMT1. 
(A) WT NRMT1 fully trimethylates RCC1 (me3RCC1) in less 
than 30 min, compared to (B) N209I and (C) P211S, which 
exhibit primarily monomethylation/dimethylation (me1/2RCC1) 
until 2h, where trimethylation levels begin to rise.  The 
corresponding decrease in monomethylation/dimethylation is 
evident only after 3h.  These data indicate N209I and P211S 
are still distributive enzymes capable of trimethylation, 
but they are slower at converting monomethylation to 
trimethylation.  Total RCC1 is shown as a loading control.  
Control (Cont.) reactions done without enzyme.  (D) At low 
substrate levels, WT NRMT1 proceeds almost completely to 
trimethylation.  As substrate concentration increases, the 
levels of monomethylation/dimethylation by NRMT1 increase 
because the ratio of unmodified substrate to previously 
methylated substrate is higher.  (E-F) At low substrate 
levels, the NRMT1 N209I and P211S mutants show no 
methyltransferase activity.  As substrate concentration 
increases, trimethylation begins to appear but does not 
reach WT levels until a 1:1 molar ratio of enzyme to 
substrate, indicating a higher substrate concentration is 
needed for optimum trimethylase activity.  Anti-NRMT1 is 
shown as a loading control for WT.  Anti-His is shown as a 
loading control for mutant NRMT1, as this NRMT1 antibody 
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recognizes an epitope containing N209 and P211 (47).  Blots 
are representative images of three independent experiments.  
Bands were quantified using ImageJ software (NIH) and 
internally normalized to brightest band of each set, which 
was set at 1.0. 
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predominantly shows trimethylation (Fig. 7D), while both 
mutants are just beginning to exhibit mono-/dimethylase 
activity (Fig. 7E,F).  At 1.0 μg substrate, WT NRMT1 still 
favors trimethylated product, while both N209I and P211S 
still favor mono-/dimethylation (Fig. 7D-F).  It is not 
until the molar amount of mutant enzyme equals the molar 
amount of substrate (1 µg of NRMT = 40 pmol; 2 µg of RCC1 = 
40 pmol) that the mutants have mono-/di- and trimethylation 
levels comparable to WT NRMT1 (Fig 7D-F).  This indicates 
the mutants require a higher substrate concentration to 
reach maximal activity. 
 
Molecular Modeling of N209I and P211S 
 
 The examination of the NRMT1 crystal structure (128) 
showed N209I and P211S to be in the peptide-binding channel 
near the aromatic residues (Y19, W20, H140) of the active 
site (132).  NRMT1 is a class I methyltransferase 
consisting of a seven-stranded b sheet surrounded by five a-
helices (128).  In addition, there are three helices in the 
N-terminus segment, a pair of b hairpins, and a series of 
loops connecting the structural elements (131).  It has 
been determined that the helices in the N-terminal segment 
cluster with loop 4 (L4) and loop 67 (L67) to create the 
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peptide-binding domain, which is integrated by residues 
L31, Y34, I37, W136, L210, P211, I214, V217, Y215, and E213 
(131).  While both N209 and P211 are in L67 (Fig. 8A), 
neither was previously predicted to directly interact with 
substrate (131). 
To determine how the N209I and P211S mutations might 
otherwise affect the peptide-binding channel, molecular 
modeling was performed (134).  The modeling revealed that 
P211 is oriented toward the peptide-binding channel, and 
its mutation to serine could alter the shape of the cavity 
itself (Fig. 8B).  Alternatively, prolines confer distinct 
shapes to unstructured regions, so its mutation to serine 
could change the configuration of L67 in an unpredictable 
manner.  Mutation of N209 to isoleucine does not make any 
visually obvious changes to the structure of the peptide-
binding channel (Fig. 8B).  However, asparagine to 
isoleucine mutations have previously been shown to affect 
protein characteristics (135).  The amide group of 
asparagine can hydrogen bond, while the isoleucine side 
chain is hydrophobic and does not.  While these hydrogen 
bonds might not be directly formed with substrate, they may 
be necessary for proper orientation of L67.  Taken together, 
I hypothesize that residues in the peptide-binding channel 










Figure 8. Molecular modeling of NRMT1 mutants. 
(A) Full crystal structure of NRMT1.  Arrow denotes loop67 
(L67, navy blue) where N209 and P211 are located.  The 
methyltransferase co-factor S-adenosyl-methionine (SAM) 
bound to the active site is indicated in gray.  (B) Model 
comparing wild type NRMT1 (green, PDB code 2EX4) to mutated 
NRMT1 (pink), as calculated by the Robetta server (136).  
The schematic shows a zoomed in area of the active site.  
Molecular modeling was performed by Janusz Petkowski, 




regulate substrate binding by altering the overall 
orientation of L67. 
 
NRMT1 Mutations Do Not Act as Dominant Negatives in Cancer 
Cells 
 
It was determined that the EZH2 Y641 mutation acted in 
a dominant manner by exogenously expressing both WT EZH2 
and Y641F EZH2 in HEK293T cells, which already harbor WT 
EZH2 activity, and monitoring H3K27me3 levels (105).  While 
expression of WT EZH2 produced a barely detectable increase 
in H3K27me3, expression of Y641F EZH2 resulted in a 
significant increase in H3K27me3, (105) indicating even 
with WT EZH2 present, the Y641F can change H3K27 
methylation levels.  HEK293T cells expressing Y641F EZH2 
were also more resistant to a small-molecule inhibitor of 
single-carbon transfer methyltransferases (105). 
 To monitor if the P211S and N209I NRMT1 mutations 
worked in a similar dominant fashion, both were exogenously 
expressed using lentivirus at an MOI of 1 in A549 human 
lung carcinoma cells (as P211S was originally found in a 
lung cancer sample) (137).  Though expression levels of WT, 
N209I, and P211S NRMT1 were similar, only WT NRMT1 showed a 
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slight increase in N-terminal trimethylation levels (Fig. 
9A).  Neither N209I nor P211S significantly changed either  
mono-/di- or trimethylation levels of endogenous RCC1 (Fig. 
9A), indicating they are not acting in a dominant negative 
manner.  Expression of the mutants also did not 
significantly affect cellular proliferation (Fig. 9B). 
The role of NRMT1 in lung cancer remains unclear, though it 
has been found to have slightly decreased expression in 
non-small cell lung carcinoma (138).  NRMT1 is most 
commonly found under-expressed in breast cancer, 
glioblastoma, and leukemia (139-142).  It has been 
correspondingly shown that in breast cancer NRMT1 is acting 
as a tumor suppressor, and its loss promotes oncogenic 
growth (50).  Conversely, NRMT1 has shown to be robustly 
overexpressed in a variety of colon cancer samples, (143-
145) where I predict NRMT1 may be acting as an oncogene. 
To monitor if the P211S and N209I mutations have a 
differential effect in a cancer type that typically 
overexpresses NRMT1, the same overexpression experiments 
were performed in HCT116 human colorectal carcinoma cells.  
As in A549 cells, neither expression of P211S nor N209I 
were able to change mono-/di- or trimethylation levels of 
endogenous RCC1 (Fig. 9C) or alter cellular proliferation 
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Figure 9. NRMT1 mutants are not dominant negatives but 
reduce N-terminal trimethylation when homozygous. 
(A-D) When overexpressed in (A) A549 or (C) HCT116, neither 
the N209I nor the P211S NRMT1 mutants (A,C) alter the level 
of RCC1 N-terminal monomethylation/dimethylation 
(me1/2RCC1) or trimethylation (me3RCC1) or (B,D) cellular 
growth rates as compared to control cells expressing empty 
vector (-) or cells overexpressing wild type (WT) NRMT1.  
When expressed in HCT116 cells where NRMT1 expression has 
been knocked out (KO) through CRISPR/Cas9 genome editing, 
(E) neither the N209I nor P211S mutant can restore N-
terminal trimethylation levels, and (F) P211S is also 
unable to rescue the growth defect seen with NRMT1 
knockout.  Each data point represents the mean ± SEM of 
three independent experiments.  * denotes P < 0.05, 
determined by a paired two-tailed Student’s t-test.  GAPDH 
is shown as a loading control.  Anti-Mettl11a/NRMT1 (Abcam) 
used to determine WT and mutant NRMT1 expression levels.  
Blots are representative images of three independent 
experiments.  Bands were quantified using ImageJ software 
(NIH) and internally normalized to wild type untransfected 
bands, which were set at 1.0.  Work in this figure was 
performed by John Tooley, State University of New York at 
Buffalo.  
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A CRISPR/Cas9 HCT116 NRMT1 knockout strain was 
recently made, which completely lacks NRMT1 expression and 
N-terminal trimethylation, while maintaining wild type 
mono-/dimethylation levels (Fig. 10 and Fig. 9E).  To test 
if the P211S and N209I mutations could alter cellular 
phenotypes as homozygous mutations, the NRMT1 knockout cell 
lines were transduced with both mutations at an MOI of 1.  
As opposed to rescue with WT NRMT1, neither mutation could 
rescue N-terminal trimethylation levels, though they were 
expressed at similar levels for over 72 hours (Fig. 9E).   
These data confirm the impaired biochemical activities 
of these mutants cannot be overcome in cells with 
endogenous substrate levels, even after prolonged exposure. 
As loss of NRMT1 function has been shown to alter cellular 
growth rates, the ability of N209I and P211S to rescue 
cellular proliferation rates in the HCT116 NRMT1 knockout 
line was also performed.  As compared to control pSpCas9 
transfected cells, the NRMT1 knockout strain grows 
significantly slower (Fig. 9F).  This would be expected if 
NRMT1 acts as an oncogene in this cell type.  Rescue with 
transduction of WT NRMT1 restores proliferation rates (Fig. 
9F).  Surprisingly, expression of the N209I mutant also 
restores proliferation rates, though the P211S mutation 






















WT:  ACG GTG GAC GGC ATG CTT GGG…
Thr Val     Asp    Gly Met    Leu Gly
10 bp deletion
Clone #6:  ACG TGC TTG GGG GGT ATG GCC…
Thr Cys Leu Gly Gly Met    Ala
C
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Figure 10. NRMT1 genome editing in HCT116 cells. 
(A) NRMT1 target site selected for sgRNA design.  
Protospacer adjacent motif (PAM) highlighted in red.  (B) 
Western blot analysis of first six expanded clones.  All 
clones had reduced NRMT1 (25 kD band) and N-terminal 
trimethylation (me3-RCC1) levels as compared to control 
(Cont.) cells transfected with empty pSpCas9(BB)-2A-Puro.  
*denotes non-specific band recognized by NRMT1 antibody.  
(C) DNA frameshift mutation found in clone #6, which was 
subsequently used in all experiments.  Cell line was 




proliferation and the other cannot, though neither restores 
N-terminal trimethylation levels, now remains to be 
determined.  These data indicate the NRMT1 mutations are 
loss-of-function mutations and not neomorphic gain-of-
function alleles, like the EZH2 mutations, and will need to 
become homozygous or combined with other NRMT1 loss-of-
function mutations before effects on proliferation and 




My work contributed to the findings that describe a 
biochemical alteration in NRMT1 and NRMT2 methyltransferase 
activities resulting from mutations identified in human 
cancer samples.  In addition, I also showed that NRMT1 
mutations in the conserved aromatic residues of the active 
site did not result in switched catalytic specificities or 
altered levels of substrate methylation. 
This is contrary to what is seen in the SET domain 
histone methyltransferase EZH2, where mutation of its Y641 
residue to either a phenylalanine or asparagine changes its 
catalytic specificity from a monomethylase to a 
trimethylase (105).  There are a few possible explanations 
for this divergence.  First, while EZH2 is a SET domain 
methyltransferase, NRMT1 and NRMT2 are seven-b-strand 
methyltransferases (46).  Though both types of 
methyltransferases contain a series of aromatic residues in 
their active site that are reminiscent of the aromatic 
cages found in methyllysine-binding proteins and likely 
contribute to substrate specificity, they are structurally 
distinct methyltransferases which may have different modes 
of substrate recognition (46,105). 
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Alternatively, in addition to the aromatic residue 
composition, there is a second structural feature of NRMT1 
and NRMT2 that could dictate catalytic specificity.  
Despite the high sequence conservation between NRMT1 and 
NRMT2, NRMT2 possesses an extra 60 amino acid N-terminal 
domain “tail” which is not found in NRMT1 (46).  Given the 
apparent flexibility of this tail, it is possible it could 
partially fold over the active site and limit substrate 
entrance.  This would then take precedence over the 
aromatic residues in substrate selection and binding. 
A similar regulatory mechanism is seen in the human 
arginine methyltransferase PRMT1 (146).  PRMT1 has seven 
alternative splice variants that differ in their N-terminal 
composition, and these unique sequences influence both 
catalytic activity and substrate specificity (146).  To 
address this possibility for NRMT1 and NRMT2, I attempted 
to make NRMT2 with the tail domain deleted and NRMT1 with 
the tail domain added.  Future experiments will be needed 
to fully address this issue. 
Although the NRMT1 aromatic cage mutants showed no 
alteration in catalytic specificity, the cancer mutations 
N209I and P211S (endometrial and lung, respectively) showed 
a significant decrease in trimethylase activity and a 
significant increase in mono-/dimethylase activity.  The 
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NRMT2 breast cancer mutation V224L also showed a 
significant decrease in monomethylase activity but lacked a 
reciprocal gain in trimethylation activity.  The recently 
solved crystal structures of NRMT1 complexed with substrate 
peptides illustrates that N209I and P211S are in the 
peptide binding channel, (131) and V224 is adjacent to an 
asparagine that forms both hydrogen bonds and electrostatic 
interactions with substrate, (131) indicating the mutations 
do not directly change catalytic specificity but alter 
substrate preference.  This is validated by my western 
blots showing N209I and P211S are still distributive 
enzymes capable of trimethylation.  However, they are less 
efficient at methylating unmodified substrate and 
converting mono-/dimethylated substrate into trimethylated. 
Whether these mutations can act as drivers of 
oncogenesis or promote further oncogenic transformation 
remains to be elucidated.  My data indicate it may depend 
on the type of cancer it is found in.  As seen in the 
HCT116 NRMT1 knockout line, cancers that typically 
overexpress NRMT1 may find mutants with decreased 
trimethylase activity detrimental to their growth.  In 
addition, loss of N-terminal trimethylation has been shown 
to impair DNA repair, (50,52) so it may also make these 
tumors more sensitive to DNA damaging chemotherapeutics or 
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g-irradiation.  Cancers, such as breast, that become more 
oncogenic with loss of NRMT1 (50) may find these mutations 
as helpful drivers of oncogenesis, though the potential for 
increased sensitivity to DNA damaging agents would remain. 
 In the case of NRMT1, I propose its ability to work 
both as an oncogene and a tumor suppressor is likely 
dependent on which pathways are driving oncogenesis in 
specific tissues.  For example, one well-studied NRMT1 
target is the tumor suppressor retinoblastoma protein (Rb).  
It was previously shown that NRMT1 is acting as a tumor 
suppressor in estrogen receptor (ER) positive MCF-7 breast 
cancer cells, as its loss promotes DNA damage accumulation, 
and increased proliferation, migration, and xenograft tumor 
formation (50).  Patients with ER+ tumors have poorer 
disease outcomes if they have an Rb mutation (147).  If 
methylation of Rb by NRMT1 activates Rb-dependent 
transcription, loss of NRMT1 could mimic an Rb mutation and 
increase oncogenicity. 
In contrast, NRMT1 is found overexpressed in colon 
cancers, (143-145) indicating it may be acting as an 
oncogene in this tissue.  One difference between breast 
cancers and colon cancers is that colon cancer cells 
harboring activating K-Ras mutations require wild type Rb 
for oncogenic transformation and prevention of apoptosis 
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(148,149).  Thus, in this particular tumor type, 
overexpression of NRMT1 could be beneficial. 
Little is known about NRMT1 expression levels in human 
lung cancer samples, though one study found a 1.5-fold 
decrease in NRMT1 expression in non-small cell lung 
carcinomas (NSCLC) (138).  Unlike small cell lung 
carcinomas (SCLC), which frequently harbor Rb mutations, 
NSCLC tumors favor mutation in CDKN2A (150).  As an 
inhibitor of MDM2 activity, CDKN2A indirectly controls both 
p53 and Rb protein levels, so NSCLC cancer harboring both a 
CDKN2A and NRMT1 mutation would have reduced levels of Rb 
with potentially reduced activity. 
In fact, the NRMT1 P211S mutation was found in a cell 
line derived from a metastatic lymph node of a patient with 
NSCLC (137), and Functional Analysis through Hidden Markov 
Models (FATHMM), which predicts the functional consequences 
of single nucleotide variants, rates it as strongly 
pathogenic (Cosmic Catalogue of Somatic Mutations in 
Cancer).  The NRMT1 N209I mutation was identified as a 
somatic mutation in an endometrial tumor sample and also 
has a strongly pathogenic FATHMM prediction (Cosmic 
Catalogue of Somatic Mutations in Cancer).  Of the 48 
currently reported NRMT1 cancer mutations, eight are 
missense mutations in the L4 and L67 loop regions that help 
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create the peptide-binding channel, and seven of these 
eight mutations have strongly pathogenic FATHMM predictions 
(Cosmic Catalogue of Somatic Mutations in Cancer). 
My supposition that NRMT1 can act as an oncogene or a 
tumor suppressor, dependent on the type of cancer, is based 
on the under- or overexpression of NRMT1 seen in different 
cancer types.  This dual type of behavior is not uncommon.  
There are proteins which have been documented to act as an 
oncogene or a tumor suppressor in different cancers, or 
even in the same cancer type.  E-cadherin is commonly 
considered a tumor suppressor, and its loss occurs in many 
epithelial cancers, including colon and liver cancers 
(151,152).  On the other hand, the overexpression of E-
cadherin has also been observed in advanced glioblastoma 
tumors, and its knockdown in SF767 glioma cells inhibited 
proliferation (153). 
Another example is RAD9, which participates in DNA 
repair and cell cycle regulation.  It can act as an 
oncogene in breast cancer, and its overexpression has also 
been correlated with prostate and thyroid cancers.  It has 
been additionally reported that deletion of RAD9 in mouse 
keratinocytes leads to the development of skin cancer, 
suggesting its role as a tumor suppressor in such a context 
(154).  Lastly, RASSF1 seems to function as a tumor 
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suppressor in most neuroendocrine lung tumors, but as an 
oncogene in neuroendocrine lung tumors that are high grade 
(155). 
 Why loss of N-terminal trimethylation by NRMT1 would 
result in phenotypes despite the continued presence of 
monomethylation by NRMT2 (or NRMT1 mutants) also remains to 
be elucidated.  As with lysine methylation, I predict the 
different levels of N-terminal methylation promote 
different functional outcomes.  For example, in the case of 
histone H4 lysine 20 (H4K20) methylation, monomethylation 
promotes transcriptional elongation by recruiting the MSL 
complex, increasing local histone H4 lysine 16 acetylation, 
and releasing RNA polymerase II (Pol II) into active 
elongation (22).  In contrast, H4K20 trimethylation 
promotes Pol II pausing by inhibiting MSL recruitment (22).  
These distinct functional outcomes are driven by the 
specificity of the MSL chromodomain for H4K20 mono- and 
dimethylation and its inability to bind trimethylation 
(77).  Whether the different levels of N-terminal 
methylation also have readers with distinct structural 
domains or whether monomethylation simply is unable to 
promote strong DNA-protein interactions are currently under 
investigation. 
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 The discovery of the Y641 EZH2 mutations as drivers of 
B cell lymphoma has led to the development of many new EZH2 
inhibitors.  Two of these inhibitors, GSK126 and EPZ-6438, 
both highly selective S-adenosyl-methionine-competitive 
small molecule inhibitors, have been respectively shown to 
inhibit the proliferation of EZH2 diffuse large B-cell 
lymphoma cell lines and mouse xenografts expressing the 
Y641 mutation (156-158).  However, unlike the EZH2 Y641 
mutations, the identified NRMT1 mutations are not gain-of-
function, and therapeutic use of NRMT1 inhibitors would 
have to be context specific. 
In tumors such as colorectal, that significantly 
overexpress NRMT1, NRMT1 inhibitors could be a viable 
therapeutic option (143-145).  In breast cancers, however, 
use of NRMT1 inhibitors alone could be detrimental, but 
beneficial in combination with DNA-damaging 
chemotherapeutics or g-irradiation.  As it has been shown 
that neither the N209I or P211S NRMT1 mutations can restore 
N-terminal trimethylation after loss of NRMT1, homozygosity 
for these mutations may also be a useful marker for tumors 
especially susceptible to chemo and irradiation therapies.  
Novel bisubstrate analogues and potent inhibitors of NRMT1 
have recently been designed and continue to be optimized, 
(159,160) and it will be interesting to see if any of the 
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derivatives affect cancer cell proliferation and/or 







CHAPTER III: ASSESSING THE CELLULAR EFFECT OF NRMT1 MUTANTS 
DURING THE DNA DAMAGE RESPONSE 
 
BACKGROUND 	
From the data in Chapter II, I demonstrated that the 
NRMT1 cancer mutants (N209I, endometrial cancer; P211S, 
lung cancer) impair catalytic activity in vitro (Figs. 2, 
5-7) (109).  However, the significance of this in a 
cellular context is unclear and is the focus of the work 
presented in this chapter. 
In the MCF-7 and LCC9 breast cancer cell lines, the 
loss of NRMT1 resulted in an increased sensitivity to DNA 
damage (50,51).  Additionally, NRMT1 knockout MEFs display 
an increased sensitivity to oxidative damage (51).  
Together, these data suggest that NRMT1 may be crucial for 
cell survival in response to cellular insults.  Given that 
the N209I and P211S mutants are also incapable of rescuing 
N-terminal trimethylation activity in cells (Fig. 9) (109), 
I hypothesize that they will be unable to promote cell 
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survival of NRMT1 knockout cells in response to DNA 
damaging agents. 
DNA damaging agents are often employed as 
chemotherapeutic agents in the treatment of cancer.  Two 
examples include etoposide (brand name Etopohos) and 
doxorubicin (brand name Adriamycin).  Etoposide 
intercalates with DNA, causing DNA DSBs, and is also a 
topoisomerase II inhibitor.  It is capable of inducing 
caspase-mediated apoptosis at high concentrations (161-
163).  Doxorubicin belongs to the anthracycline class of 
drugs (161), and it also intercalates with DNA, causing DNA 
DSBs.  Additionally, it can also cause oxidative stress 
(161,164-166), leading to the mitochondrial route of 
apoptosis (167-169).  While NRMT1-depleted cells have a 
heightened sensitivity to etoposide (50), their response to 
doxorubicin remains untested. 
To begin to address this question, I utilized NRMT1-
deficient HCT116 cells that had already been generated 
using CRISPR technology (Fig. 10; hereby referred to as KO 
cells).  An additional advantage of using these cells is 
based on their similarity to MCF-7 cells, in regards to 
having wild-type p53 status (170).  Thus, to investigate 
whether the N209I or P211S mutations in NRMT1 would have 
any functional consequence in the context of cellular 
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proliferation or DNA damage, I expressed these mutants, as 
well as wild-type NRMT1, into the KO cell line, and 
assessed their sensitivity towards doxorubicin. 
The cellular response towards DNA damaging agents 
(specifically, doxorubicin) has been extensively 
characterized (171).  In the absence of p53, or its 
downstream target p21, cells exhibit an increase in 
doxorubicin-induced cell death (172).  Thus, as an 
additional measure, I monitored p53 and p21 expression in 
my cell lines.  
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MATERIALS AND METHODS 
 
Constructs and Antibodies 
 
To generate C-terminal GFP-tagged NRMT1 constructs, 
human NRMT1 (GE Dharmacon, Marlborough, MA), which had been 
subcloned into the pKGFP2 vector, was used as the template 
for site-directed mutagenesis to produce N209I and P211S 
NRMT1 using the Quikchange site-directed mutagenesis 
protocol (Agilent Technologies, Santa Clara, CA).  The 




Both mutants were confirmed by DNA sequencing. 
 Primary antibodies used for western blots are as 
follows: 1:5000 polyclonal rabbit anti-me1/2RCC1 (mono-
/dimethylated SPK-RCC1) (120), 1:10,000 polyclonal rabbit 
anti-me3RCC1 (trimethylated SPK-RCC1) (120), 1:1000 
polyclonal goat anti-RCC1 (Santa Cruz Biotechnology, sc-
1162, Santa Cruz, CA), 1:2000 polyclonal rabbit anti-NRMT1 
(128), 1:500 monoclonal rabbit g-H2AX (Abcam, 20E3, 
Cambridge, United Kingdom), 1:1000 monoclonal rabbit HSP90 
(Cell Signaling Technology, C45G5, Danvers, MA), 1:1000 
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monoclonal mouse a-tubulin (Sigma Aldrich, St. Louis, MO), 
1:1000 monoclonal mouse p53 (Santa Cruz Biotechnology, sc-
098), 1:1000 polyclonal rabbit p21 (Santa Cruz 
Biotechnology, sc-397), 1:1000 monoclonal mouse Rb, and 
1:1000 monoclonal mouse DDB2 (Abcam, ab51017).  1:1000 
polyclonal rabbit anti-Mettl11a/NRMT1 (Abcam, ab102664) was 
used to detect KO+WT, and KO+N209I and KO+P211S NRMT1. 
Secondary antibodies used were as follows: goat anti-rabbit 
IRDyeÒ 680 RD (Li-Cor, 926-68071, Lincoln, NE), goat anti-
mouse IRDyeÒ 800 CW (Li-Cor, 926-32210), and donkey anti-
goat IRDyeÒ 800 CW (Li-Cor, 925-32214).  All antibodies were 
diluted in 2% BSA (in TBST).  
SDS polyacrylamide gel electrophoresis (SDS PAGE) was 
performed using tris-glycine separation with running buffer 
(25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3).  Gels were 
run at 125V until the bromophenol blue tracker dye reached 
the end of the gel (approximately 90 minutes).  Proteins 
were transferred to nitrocellulose membranes for 90 minutes 
at a constant current of 400mA in transfer buffer (25 mM 
Tris, 192 mM glycine, pH 8.3), which were then blocked 
using 2% BSA in TBST for one hour at room temperature. 
After the blocking step, incubation with the primary 
antibodies was performed at 4 °C overnight (18-20 hours) on 
an end-over-end rocker.  Washing was performed using TBST. 
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Incubation with secondary antibodies was performed for one 
hour at room temperature.  After the final washing steps, 





HCT116 human colorectal carcinoma cells lines (a 
generous gift from Dr. Ian Macara, Vanderbilt University) 
were maintained in Dulbecco’s Modified Eagle Medium (DMEM) 
(Corning Life Sciences, Manassas, VA) with 10% fetal bovine 
serum (FBS) (VWR, Radnor, PA) and 1% penicillin-
streptomycin-glutamine (P/S/G) (Life Technologies) and were 
used at a passage number of less than 25.  To generate 
KO+WT (WT), KO+N209I (N209I), and KO+P211S (P211S) cells 
(referred to collectively as rescue cells), NRMT1 KO cells 
were transduced with WT NRMT1, N209I, and P211S lentivirus 
(production detailed in Chapter II Materials and Methods) 
to a MOI of 1.  Calculations performed to estimate MOI are 
based on the detection of GFP-positive cells by microscopy, 
and the dilution of virus necessary to achieve this.  
Virus-containing media was replaced with virus-free media 
three days later. 
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Cell Growth Assays and Drug Treatment 
 
Seeding conditions were 5.0 X 104 cells per well in 12-
well plates (only fig. 14 HCT116 toleration of doxorubicin 
treatment), 2.4 X 104 cells per well in 24-well plates, or 
1000 cells per well in 96-well plates; figure legends 
indicate which condition was used.  For viability (cell 
growth) assays (CellTiter 96â AQueous One Solution Cell 
Proliferation Assay), cells were plated in triplicate in 
24-well (or 96-well) plates in 500 µL (or 100 µl) of media.  
For experiments examining DNA damage, cells were treated 
with doxorubicin (dox) (Sigma Aldrich) at 0, 0.1, or 1 µM 24 
hours following seeding.  After the treatment time or day 
of measured growth (indicated by figure legend), or 
recovery time post-treatment (48 hours), 80 µl (for 24-well 
plates) or 20 µl (for 96-well plates) of Aqueous One 
Solution (Promega, Madison, WI) was added to all 
replicates, and the absorbance at 490 nm was read after two 
hours.  Data was analyzed by two-way ANOVA and Tukey’s 
post-hoc test. 
For western blots, cells were seeded according to 
either seeding condition outlined above; figure legends 
indicate which condition was used.  Cells were plated and 
treated as indicated above.  Following the indicated 
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treatment (24 hours) or recovery time post-treatment (48 
hours), cells were lysed in 2X Laemmli’s SDS-Sample Buffer 
(4X, Boston Bioproducts, Ashland, MA) supplemented with b-




 To assess the subcellular localization of the mutants, 
3.0x105 HCT116 cont. cells were seeded on coverslips in 6-
well plates.  The jetPRIMEÒ transfection reagent (Polyplus, 
New York, NY) was used to transiently transfect 0.5 µg WT 
NRMT1, N209I, or P211S, which were all C-terminally GFP-
tagged.  For each transfection, 2 µl of jetPRIME reagent was 
added to the DNA in 200 µl of the provided buffer.  After an 
incubation of 25 minutes, the transfection mixture was 
added directly to the cells.  18 hours post-transfection, 
media was removed, cells were washed with PBS and then 
fixed in 10% formalin for 10 minutes at room temperature.  
Coverslips were mounted with Vectashield containing DAPI 
(Vector Laboratories, Burlingame, CA).  Cells were imaged 
using a confocal fluorescence microscope (Olympus IX SLA).  
Images were then imported into Photoshop (Adobe Systems, 
Inc.) for processing.  Images are from one section and are 
not an overlay. 
	 99	
 For studies with doxorubicin and g-H2AX foci 
visualization, 5.0x105 HCT116 cont. and NRMT1 KO cells were 
seeded on coverslips in 6-well plates.  One day after 
seeding, media was removed, and cells were treated with 0, 
0.1, or 1 µM doxorubicin for 24 hours.  Cells were fixed in 
10% formalin as above, followed by permeabilization in 0.5% 
Triton X-100 in PBS for 5 minutes at room temperature.  
Cells were then blocked for one hour in 2% BSA/1% goat 
serum in PBS.  Stain and antibodies used are as follows: 
primary 1:500 rabbit g-H2AX (Abcam, 20E3), prepared in 2% 
BSA/1% goat serum in PBS; 1:250 rhodamine phalloidin 
(Molecular Probes, R415, Eugene, OR), prepared in 2% BSA/1% 
goat serum in PBS; and secondary 1:1000 goat a-rabbit Alexa 
FluorÒ 488 (Invitrogen, A11008, Carlsbad, CA), prepared in 
2% BSA/1% goat serum in PBS.  Primary antibody incubation 
was one hour at room temperature; rhodamine phalloidin and 
secondary antibody incubation was for 30 minutes at room 
temperature in the dark.  Coverslips were mounted with 
Vectashield containing DAPI (Vector Laboratories).  g-H2AX, 
phalloidin, and DAPI were visualized by confocal microscopy 





siRNA Knockdown Experiments 
 
 To assess the effects of transient knockdown of NRMT1 
in HCT116 cells, cells were seeded at a density of 2.4 X 104 
cells per well in a 24-well plate.  Two days after seeding 
(when cells had reached approximately 70% confluency), 
transfection was performed using 10 pM siRNA.  The target 
sequences for the siRNA oligos utilized are as follows: 
NRMT1 a, 3’UTR: CTGGCAGGAGAAACTGAGGAA 
NRMT1 b, 3’ UTR: GAGTGTCGAGGCACCACTAAA 
NRMT1, ORF: GGCCCGAACAAGACAGGAAtt (sense); 
UUCCUGUCUUGUUCGGGCCtt (antisense) 
21 hours post-transfection, media was replaced, and cells 
were treated with 1 µM doxorubicin or 250 µM etoposide for 
six hours.  Cell lysates were then analyzed for NRMT1 




Mutant NRMT1 Methylation Pattern Is Not Unique to RCC1 
 
From Chapter II, the methylation pattern for RCC1 
displayed by the NRMT1 cancer mutants was established using 
in vitro methyltransferase assays.  To determine the 
pattern in a cellular context, I independently re-
established these cell lines by stably expressing these 
mutants in HCT116 cells lacking endogenous NRMT1. 
Specifically, I used lentivirus expressing WT, N209I, and 
P211S NRMT1.  The cells were established, and the 
expression was confirmed by western blot (Fig. 11).  As a 
CRISPR control, I used cells expressing pSpCas9 only 
(hereby referred to as cont. cells). 
Western blots with the trimethylated SPK (me3RCC1) 
antibody shows that only WT NRMT1 was able to rescue the 
trimethylation pattern (Figs. 9, 11, 23).  Thus, while the 
in vitro data suggested that the NRMT1 cancer mutants 
possessed an inefficient ability to trimethylate 
substrates, they could not do so in a cellular context. 
NRMT1 recognizes over 300 putative targets (44) with 
many different consensus sequences; however, only a handful 






Figure 11. NRMT1 KO cells transduced with lentivirus. 
NRMT1 KO cells were transduced with lentivirus expressing 
WT, N209I or P211S NRMT1 at a MOI of 1.  After cells were 
established, protein lysates were obtained, and western 
blot performed with the indicated antibodies.  NRMT1 
expression and trimethylation of RCC1 in WT lane is 
comparable to that of cont., while this is barely 
detectable in the N209I and P211S lanes.  Mono-
/dimethylation of RCC1 is the same across all five cell 
lines.  The levels of RCC1 are also the same in all lines.  
HSP90 was used as a loading control.  Shown is a 
representative Western blot from three independent 
experiments.  
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From Figure 23, the band that migrates at 45 kD (indicated 
by the asterisk) is RCC1. 
The other prominent band detected by the tri-SPK  
antibody migrates at approximately 20 kD.  According to 
Petkowski et al. (44) (who expanded the originally defined 
NRMT1 consensus sequence, as well as performed additional 
in-depth work to pinpoint putative NRMT1 targets), a 
protein of this size possessing the SPK sequence could 
potentially be the VCX-A protein.  However, VCX-A has only 
been detected in the testis and germ cells, linking it with 
potential roles in spermatogenesis (173).  Thus, the exact 
identity of this band in HCT116 cells has yet to be 
elucidated.  Nevertheless, the presence of this band was 
also rescued by wild-type NRMT1 in the KO cells. 
 
N209I Subcellular Localization Differs from WT NRMT1 
 
 The subcellular localization of WT NRMT1 is 
predominantly nuclear (46,47).  To determine if the NRMT1 
mutants localize appropriately, I performed confocal 
microscopy.  HCT116 cont. cells were transfected with C-
terminally GFP-tagged WT, N209I, or P211S constructs, and 
processed for confocal microscopy.  The nucleus was 
visualized by DAPI staining.  From two independent 
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experiments, WT NRMT1 displayed the predominantly nuclear 
localization pattern, with minimal cytoplasmic 
localization, as expected (Fig. 12).  Similarly, the 
subcellular localization of the P211S mutant was also 
predominantly nuclear (Fig. 12).  In contrast, the N209I 
mutant exhibited noticeably more cytoplasmic localization 
(Fig. 12).  Thus, in addition to loss of trimethylation 
activity, the N209I mutant may exhibit reduced nuclear 
localization in cells. 
 
Viability Studies of HCT116 Cells 
 
 Prior to studying DNA damage in the HCT116 cells, I 
examined the proliferation levels of the cell lines that I 
re-established, to determine if the cancer mutants could 
rescue the proliferation defect in KO cells that was 
previously described (109).  Using the CellTiter assay, I 
assessed the proliferation of the five cell lines on days 
0, 1, 3, and 5 after seeding.  A total of nine experiments 
were performed on separate days with a summary graph shown 
in Figure 13 (Fig. 24 in the Appendix). 
 The summary graph shown in Figure 13 exemplifies the 
type of data recorded.  In eight out of the nine 










Figure 12. Subcellular localization of WT and mutant NRMT1. 
(A-B) HCT116 cells were transiently transfected with C-
terminally GFP-tagged WT, N209I or P211S NRMT1.  After 24 
hours, cells were processed for confocal microscopy using 
the Olympus IX SLA microscope.  DAPI, GFP, and merge images 
are shown.  Images were obtained using a 40X objective with 
3.0X digital magnification.  Bar, 20 µm.  Images are from 
one section and are not an overlay.  WT and P211S NRMT1 
show predominantly nuclear localization.  N209I manifests 
greater cytoplasmic localization, compared to WT.  




























Figure 13. Viability studies of HCT116 cells. 
Four sets of triplicates were made for each of the five 
HCT116 cell lines.  Cells were seeded at a density of 1000 
cells per well in 96-well plates on day 0.  On the day of 
plating (day 0), 20 µl of Aqueous One Solution (Promega, 
Madison, WI) was added to the first set of triplicates for 
each cell line, and the absorbance at 490 nm was read after 
two hours.  Readings were also taken on days 1, 3, and 5.  
Raw absorbance values are shown on the Y-axis.  Results 
shown are the mean ± standard deviation of data from nine 
independent experiments and triplicate measurements per 




cont. cells (Figs. 13, 24), in agreement with what I 
previously reported (109).  This is especially apparent on 
Day 5 of the assay (Figs. 13, 24).  However, in my 
experiments, the expression of WT protein into the KO cells 
did not rescue the proliferation defect as was previously 
shown (109). 
 
DNA Damage Studies of HCT116 Cells Towards Doxorubicin 
  
I next assessed whether my cell lines would exhibit 
differences in response to DNA damage, given that previous 
work demonstrated that NRMT1-depleted cells have a 
heightened sensitivity to DNA damaging agents (50,51).  For 
example, NRMT1 knockdown breast cancer cells treated with 
the DNA-damaging agent etoposide had slower rates of 
proliferation, as well as an increase in g-H2AX foci, which 
is an early indicator of DNA damage (50,174,175).  I 
decided to use doxorubicin as the DNA damaging agent, given 
that the effect of this drug has been well characterized 
(171). 
Typically, a dose of 0.1-1.0 µM doxorubicin causes cell 
death in HCT116 cells after 24 hours (172).  Prior to 
determining the effects of doxorubicin on DNA damage 
signaling, cells were first treated to confirm that 
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doxorubicin caused cell death in my HCT116 cell lines.  
HCT116 cont. and NRMT1 KO cells were treated with 0.1 or 1 
µM doxorubicin for 24 hours or left untreated as a control 
(Fig. 14).  Cells were then allowed to recover for 48 hours 
following doxorubicin treatment.  The micrographs from two 
independent experiments are shown in Figure 14.  As 
expected, doxorubicin caused cell death at both 
concentrations, but especially at 1 µM (Fig. 14). 
To quantitatively measure the cell viability in 
response to doxorubicin, I performed CellTiter assays (the 
reduction of a metabolite is correlated to the number of 
viable cells).  I first assessed this in the cont. and KO 
cells after treating with doxorubicin for 24 hours.  A 
total of five experiments were performed with a summary 
graph depicted in Figure 15 (Fig. 25 in the appendix).  
There was a trend for KO cells to exhibit increased 
sensitivity toward doxorubicin at 1 µM. 
I then performed four additional series of experiments 
to include the rescue cell lines.  This time, I only 
treated the cells at 1 µM doxorubicin for 24 hours, along 
with untreated controls.  The data are depicted in Figures 
16 and 26.  In this set of experiments, the KO cells were 
not consistently more sensitive to the doxorubicin 






Figure 14. HCT116 toleration of doxorubicin treatment. 
(A-B) 5.0 X 104 cells per well were seeded into 12-well 
plates.  HCT116 cont. and NRMT1 KO cells were treated with 
0, 0.1, or 1 µM doxorubicin for 24 hours.  Afterward, media 
was replaced, and cells were allowed to recover for 48 
hours.  Representative pictures were taken immediately 
following recovery period.  Experiment was performed twice; 


























Figure 15. Viability assay of doxorubicin-treated cont. and 
NRMT1 KO cells. 
2.4 X 104 cells per well were seeded into 24-well plates.  
Three sets of triplicates were made for cont. and NRMT1 KO 
cells.  CellTiter was performed on cells that were treated 
with 0.1 or 1 µM doxorubicin (or the untreated controls) for 
24 hours.  Following treatment, 80 µl of Aqueous One 
Solution was added to each well, and the absorbance at 490 
nm was read after two hours.  Y-axis units are arbitrary 
units of absorbance at 490 nm.  Results shown are the mean ± 
standard deviation of data from five independent 
experiments and triplicate measurements per experiment.  





























Figure 16. Viability assay of doxorubicin-treated cells. 
2.4 X 104 cells per well were seeded into 24-well plates.  
Two sets of triplicates were made for each cell line.  
CellTiter was performed on cells that were treated with 1 µM 
doxorubicin (or the untreated controls) for 24 hours.  
Following treatment, 80 µl of Aqueous One Solution was added 
to each well, and the absorbance at 490 nm was read after 
two hours.  Y-axis units are arbitrary units of absorbance 
at 490 nm.  Results shown are the mean ± standard deviation 
of data from four independent experiments and triplicate 
measurements per experiment.  Individual experimental 
results are shown in Figure 26. 
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reproducible.  Also, similar to Figure 13, WT cells did not 
rescue proliferation levels, and neither mutant cell line 
grew significantly differently than the KO cells. 
Since my data thus far suggested that NRMT1 did not 
have an effect on cell viability after 24-hour treatment, I 
performed another set of experiments to assess whether 
NRMT1 might have a role at later time points (i.e. during 
the recovery phase).  Thus, I performed two additional 
series of experiments using 1 µM doxorubicin and assessed 
cell viability after 48 hours.  As can be seen from the 
data (Fig. 17), there was no consistent difference between 
the cell lines after treatment. 
 
Assessment of g-H2AX Foci After Treatment with Doxorubicin 
 
My data, thus far, is different than what was reported 
for the role of NRMT1 in etoposide-treated or irradiated 
breast cancer cells (50).  I therefore wanted to ensure 
that, in my experiments, I was indeed inducing DNA damage. 
When cells are exposed to ionizing radiation or other 
DNA damaging agents, the histone H2A variant, H2AX, becomes 
phosphorylated at sites of DSBs on residue Ser 139 
(referred to as g-H2AX) (174,175).  This is an early event 


























Figure 17. Viability assay of recovered doxorubicin-treated 
cells. 
2.4 X 104 cells per well were seeded into 24-well plates.  
Two sets of triplicates were made for each cell line.  
CellTiter was performed on cells that were treated with 1 µM 
doxorubicin (or the untreated controls) for 24 hours 
followed by a 48-hour recovery period.  After treatment and 
recovery, 80 µl of Aqueous One Solution was added to each 
well, and the absorbance at 490 nm was read after two 
hours.  Y-axis units are arbitrary units of absorbance at 
490 nm.  Results shown are the mean ± standard deviation of 
data from two independent experiments and triplicate 




suitable marker for this process.  Therefore, as a first 
step to assess the DNA damage in the treated cells, 
confocal microscopy was performed.  In brief, treated cells 
were fixed and probed with an antibody against g-H2AX, which 
has an epitope against the phosphorylated residue Ser 139. 
 In the absence of doxorubicin, g-H2AX foci could not be 
observed in untreated cells, as expected (Fig. 18).  
However, after 24-hour doxorubicin treatment, g-H2AX was 
readily detected.  To confirm this, I also performed 
western blot analysis using the same antibody.  In 
agreement with the confocal results, the western blots 
showed an increase in g-H2AX signal after doxorubicin 
treatment, suggesting that indeed, doxorubicin was causing 
DNA damage. Additionally, the similar levels of g-H2AX in 
all the cell lines is consistent with the proliferation 
results. 
 
Western Blot Analysis of Doxorubicin Treatment 
 
 While previous data has shown that loss of NRMT1 leads 
to an increased sensitivity to etoposide in breast cancer 
cell lines, my data shows that NRMT1 has no effect in 
doxorubicin-treated HCT116 cells.  One explanation for 






Figure 18. g-H2AX foci following 24-hour doxorubicin 
treatment. 
(A) Cells were seeded at a density of 5.0x105 cells onto 
coverslips in 6-well plates.  Cells were then treated with 
1 µM doxorubicin for 24 hours before processing for confocal 
microscopy using the Olympus IX SLA microscope to visualize 
DAPI, g-H2AX (p-H2AX), and phalloidin (actin).  DAPI, GFP, 
and merge images are shown.  Images were obtained using a 
40X objective with 3.0X digital magnification.  Bar, 20 µm.  
Images are from one section and are not an overlay.  Merge 
of each CTL (cont.) and KO condition shown on far right.  
Top two rows show untreated cells (Unt), and bottom two 
rows show cells treated with 1 µM doxorubicin for 24 hours.  
Bar, 20 µm.  (B) For western blots, cells were seeded at a 
density of 2.4 X 104 cells per well in 24-well plates.  
Western blots show doxorubicin-treated cell lysates that 
were probed for HSP90, as a loading control, and g-H2AX.  




treatments and cell lines employed.  However, it is also 
possible that compensatory changes in signaling pathways 
might be a factor.  As such, I decided to perform western 
blots to look into a few key proteins involved in the DNA 
damage response. 
For the first experiment, cont. and KO cells were 
treated with 1 µM doxorubicin for 24 hours, followed by 
recovery for 48 hours.  Untreated cells were used as a 
control.  Lysates were obtained, and western blots were 
performed with the indicated antibodies (Figs. 19 and 21).  
Tubulin was used as a loading control, and the absence of 
NRMT1 and the me3RCC1 signal confirmed the identity of the 
KO cells.  Next, I assessed the p53 and p21 levels, given 
their importance in the DNA damage response in HCT116 
cells.  After treatment with 1 µM doxorubicin for 24 hours, 
both p53 and p21 exhibited increased levels in both cell 
lines.  After an additional 48 hours (during recovery), p53 
and p21 expression were still elevated in cont. cells, when 
compared to untreated cells.  However, in the KO cells, the 
levels of these two proteins had returned to levels 
comparable to untreated cells. 
Although this observation in the differences in p53 
and p21 levels seemed promising, subsequent experiments 





Figure 19. DNA damage signaling of cont. and NRMT1 KO 
cells. 
5.0 X 104 cells per well were seeded into 12-well plates.  
Cells were then treated with doxorubicin at the indicated 
concentrations for 24 hours, and then immediately lysed 
(A), or the media was replaced, and cells were allowed to 
recover for 48 hours before lysis (B).  Western blot 
analysis was conducted using the antibodies indicated in 




series of experiments, I performed western blot analysis as 
indicated above for all five lines.  For example, in one 
set of data, after treatment with doxorubicin for 24 hours, 
p53 expression was elevated (Figs. 20A and 21).  However, 
p21 expression was barely detectable. 
In another set of experiments, I performed western 
blot analysis during the recovery period (Figs. 20B and 
21).  In this instance, p53 expression was elevated when 
compared to untreated cells; however, the levels of p53 
were the same in each line.  Thus, the difference in p53 
levels observed in Figure 19 was not reproducible. 
Finally, I also evaluated a couple of NRMT1 substrates 
to see if they exhibited expression differences.  
Specifically, I looked at Rb and DDB2, which are known to 
be involved in the DNA damage response (50).  As shown in 
Figure 20B, there was no appreciable difference in the 






Figure 20. DNA damage signaling of rescue cell lines. 
The five HCT116 cell lines were seeded at 2.4 X 104 cells 
per well in 24-well plates.  Cells were then treated with 0 
or 1 µM doxorubicin for 24 hours, and then immediately lysed 
(A), or the media was replaced, and cells were allowed to 
recover for 48 hours before lysis (B).  Western blot 
analysis was conducted using the antibodies indicated in 








Figure 21. DNA damage signaling quantification. 
Densitometry quantification of p53 (A) and p21 (B) bands 
for the 1 µM doxorubicin treatment.  The quantification 
pertains to western blots displayed in figures 19 and 20.  
For comparison purposes, cont. 24h treatment was set to 
1.0.  Quantification for p53 was performed from three 
independent experiments, while quantification for p21 was 
performed from two independent experiments (blank p21 blots 





Recent work has experimentally verified a handful of 
predicted NRMT1 substrates and has determined that the N-
terminal trimethylation by NRMT1 is necessary for their 
function (20,52,118,119).  Studies have furthermore 
detailed the peptide-binding channel of NRMT1 (110), as 
well as resolved the enzymatic mechanism of NRMT1 (133).  
Despite this crucial work to uncover basic knowledge about 
NRMT1, little attention has been devoted to the impact of 
NRMT1 cancer mutants on basic cellular function and the 
response to DNA damage.  Importantly, therefore, my work 
was the first attempt to address the role of the NRMT1 
cancer mutants N209I (endometrial) and P211S (lung) in the 
DNA damage response. 
I first examined the mutant NRMT1 methylation pattern 
in cells.  Despite my in vitro data showing that the N209I 
and P211S mutants are catalytically inefficient and slower 
enzymes (Chapter II), they both lacked the ability to 
rescue trimethylation in HCT116 cells.  The reason for the 
difference between the in vitro and cellular data is 
unknown but could potentially be due to regulation.  In an 
in vitro methylation reaction, the only factors present are 
enzyme, substrate, and SAM methyl donor.  In a cellular 
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environment, however, there are also, likely, factors 
present that contribute to the regulation of methylation 
reactions. Future studies to identify these factors should 
provide important insight into NRMT1 function. 
I furthermore found that the N209I mutant exhibited a 
more pronounced cytoplasmic localization when compared to 
WT protein.  Although the significance of this is not 
known, one could easily speculate that this would affect 
the access of NRMT1 to its substrates or binding partners. 
Next, I examined the effect of the cancer mutants on 
cellular proliferation.  We previously reported that loss 
of NRMT1 in HCT116 cells causes decreased proliferation 
(109), an observation that I reproduced.  However, in these 
later studies, expression of WT NRMT1 failed to rescue the 
proliferation defect.  Similarly, expression of the cancer 
mutants also had no effect when compared to KO cells.  The 
data are not in agreement with what I have reported (109), 
which showed that both WT and N209I could rescue the 
proliferation defect of KO cells. 
I offer the following possibility for the above 
discrepancy.  RCC1 was one of the first NRMT1 substrates 
identified and characterized (47).  Experiments in MDCK 
cells showed that a methylation-defective mutant of RCC1 
bound to chromatin less than wild-type protein during 
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mitosis and caused spindle-pole defects (120,122).  Thus, 
the loss of NRMT1 (and defective RCC1 methylation) could 
result in adaptive changes in cells to bypass this crisis.  
This could be one plausible explanation as to why re-
expressing wild-type NRMT1 had no effect in KO cells that 
had been established.  An alternative approach to 
circumvent this problem was to introduce transient NRMT1 
deficiency by siRNA knockdown.  Unfortunately, after trying 
three different siRNA oligos, I could not achieve 
successful knockdown in HCT116 cells (Fig. 27). 
This was not a technical issue, as a control siRNA 
targeting an unrelated gene worked well (Fig. 27).  
Nevertheless, I evaluated whether expression of the NRMT1 
cancer mutants or WT protein would have any effect during 
the DNA damage response.  Although initial experiments 
suggested that KO cells were more sensitive to doxorubicin, 
those results were not reproducible.  Furthermore, the 
response of the rescue cell lines towards doxorubicin was 
not significantly different compared to that of KO cells.  
As such, I conclude that NRMT1 likely has no effect on the 
DNA damage response in HCT116 cells in response to 
doxorubicin. 
If adaptive changes have occurred in the KO cells, as 
I mentioned above, then obviously this could also be a 
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contributing factor to how the cells respond to 
doxorubicin.  Besides the possibility of adaptive changes, 
there are some other possible technical explanations for 
the discrepancy observed. 
First, cells could be positive for mycoplasma and 
affected by it.  Second, my cell lines had not been 
authenticated since the time that they were originally 
obtained from ATCC.  As these HCT116 cells were obtained 
several years ago, it is possible that cross-contamination 
or even mis-labelling had occurred.  Third, high passage 
numbers of the cells could result in genetic drift and 
alter cell characteristics and phenotypes over time.  
Additionally, the ATCC media recommendation for HCT116 
cells is McCoy’s 5A.  Despite this recommendation, I used 
DMEM media (as other studies have also done for HCT116 
cells (176,177)), which could potentially contribute to 
changes in growth or other characteristics over time. 
Lastly, an equally plausible scenario is that NRMT1 
could be crucial for the DNA damage response in breast 
cancer cell lines, but not in HCT116 cells.  In breast 
cancer cell lines, it has been shown that the depletion of 
NRMT1 and treatment with etoposide decreased cell 
viability.  The treatment also produced more g-H2AX foci in 
the NRMT1-depleted cells (50). 
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In my experiments with doxorubicin in HCT116 cells, 1 
µM treatment did not result in enhanced DNA damage 
sensitivity, unlike in the original experiments with breast 
cancer cell lines employing etoposide treatment (50).  
Thus, if the effect of the NRMT1 cancer mutants are to be 
further studied in the context of DNA damage, it would seem 





CHAPTER IV: FUTURE DIRECTIONS 
 
My dissertation research was born out of an interest 
sparked from a 2011 study.  That work demonstrated that 
some B-cell lymphoma patients possess a Y641 aromatic cage 
active site mutation in the histone methyltransferase EZH2 
(105,111,115).  The mutation was found to change the 
catalytic specificity of EZH2 from a mono- to a 
trimethylase (105,111,115).  This altered gene expression 
and increased oncogenicity (105,111,115).  These findings, 
coupled with a similarity in the spatial alignment between 
EZH2 and NRMT1/2, lead me to pursue whether the catalytic 
specificities of NRMT1 or NRMT2 are altered by their 
harbored mutations found in some cancers, or in the 
aromatic cage itself. 
My findings from Chapter II show that the aromatic 
cage mutations of both NRMT1 and NRMT2 yielded no 
significant alterations in activity when compared to the 
wild-type protein.  In contrast, some cancer mutations of 
both NRMT1 (N209I and P211S) and NRMT2 (V224L) 
significantly altered the catalytic specificity.   
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Specifically, the N209I and P211S mutants were found 
to require increased time and substrate concentration to 
match the activity of wild type NRMT1.  This lead me to 
propose that they are slower, catalytically inefficient 
enzymes.  Finally, the NRMT2 V224L breast cancer mutant had 
little detectable activity. 
In Chapter III, I sought to characterize the 
significance of the N209I and P211S mutants in a cellular 
context.  My approach was to express these mutants and WT 
NRMT1 in a knockout line that had been generated by CRISPR 
in HCT116 cells (“KO” cells).  As a control, I utilized 
HCT116 cells that went through the same process as the KO 
cells, except no guide RNAs were used – empty vector (cont. 
cells). 
Although the results in Chapter II demonstrate that 
the cancer mutants are inefficient in vitro, they seem to 
lack notable trimethylase activity in cells.  I further 
discovered that N209I had increased cytoplasmic 
localization compared to the predominantly nuclear 
localization of wild type NRMT1 (46,47) and P211S proteins.  
Whether this contributes to an oncogenic phenotype is 
uncertain at this point. 
Having established my rescue cell lines, I then 
attempted to assess the importance of the NRMT1 cancer 
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mutants in a cellular context.  Based on my data, I 
concluded that the expression of the cancer mutants or WT 
NRMT1 protein had no effect on KO cells with respect to 
proliferation.  Thus, part of my data is in contrast to 
what we previously published (109). 
Concurrently, I explored the potential effects of the 
NRMT1 mutants in the context of DNA damage, given that it 
was previously shown that shRNA knockdown of NRMT1 in 
breast cancer cells caused an increased sensitivity to DNA 
damage (50).  Using the cont., KO, and rescue cell lines, I 
induced DNA damage with the chemotherapeutic drug 
doxorubicin.  My initial observations indicated that KO 
cells may be more sensitive to doxorubicin (either by cell 
viability assay or p53/p21 induction). However, the data 
was not consistently repeatable.  In conclusion, neither 
the KO nor rescue cell lines showed a significant 
difference in doxorubicin sensitivity compared to cont. 
cells. 
 
Future Biochemical Studies for NRMT1 
 
 In Chapter II, I demonstrated that N209I (endometrial 
cancer) and P211S (lung cancer) NRMT1 mutants have 
decreased trimethylation and increased mono-/dimethylation 
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activity toward substrates.  This suggests that the mutants 
could have impaired kinetic parameters, and assays should 
be performed to determine any alterations to Km and Vmax 
values.  Given the increased need of the mutants for time 
and substrate levels, alterations to Km, or perhaps Vmax, 
seem plausible.  An increase in Km would demonstrate that 
the mutants require a higher substrate concentration to 
reach half maximal velocity, compared to WT NRMT1.  
Furthermore, a decrease in Vmax would demonstrate that the 
mutants catalyze methylation reactions at a lower rate 
compared to WT NRMT1. 
 I investigated these questions using several different 
methyltransferase assay kits, which measure levels of SAH 
(a by-product of methylation reactions).  However, using 
full-length recombinant protein, I was unable to detect 
much signal over background.  Since I can detect 
methylation of substrate by western blot, it is possible 
that these assay kits are not sensitive enough to detect 
the levels of SAH normally generated by reaction with 
NRMT1.  Given this difficulty I encountered using full-
length recombinant protein with multiple assay kits, this 
would need to be conducted using peptide substrate.  
However, as this would utilize only a small portion of the 
N-terminus of the substrate protein, this would be less 
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biologically relevant.  An alternative would be to use 
full-length protein substrate and measure the kinetics by 
radioactive means or metabolite labeling. 
 In addition to discovering the kinetics of N209I and 
P211S, the binding affinity or folding of the mutant 
proteins could also be investigated.  Besides the 
possibility of N209I and P211S possessing altered kinetic 
parameters, contributing to the observed shift in catalytic 
specificity, the mutants could also exhibit a decreased 
binding affinity for their substrates.  In order to 
determine differences in binding affinity between WT NRMT1 
and the mutants, isothermal titration calorimetry could be 
employed.  It is plausible that the mutants have decreased 
substrate binding affinity, which could additionally 
contribute to the observed change in catalytic specificity. 
 Lastly, the folding of the mutants could be studied. 
It is possible that the location of the mutants in the 
peptide-binding channel of NRMT1, and their hypothesized 
effects on the global structure (based on molecular 
modeling), could impact the folding of the proteins.  In 
order to determine if folding of the proteins are affected 
by the mutations, circular dichroism could be utilized.  A 
defect in protein folding could impact the overall 
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activity, giving the altered catalytic specificity seen 
with the mutants. 
 Studying the kinetics, binding affinity, and folding 
of N209I and P211S may contribute to general biochemical 
knowledge of the mutations.  This may be informative for 
the cancers that harbor these mutations (N209I, endometrial 
cancer; P211S, lung cancer).  
 
Future Studies for NRMT1 and the DNA Damage Response 
  
While my studies suggest that NRTM1 did not play a 
role in the DNA damage response in HCT116 cells, it was 
shown to do so in breast cancer cell lines (50).  Thus, the 
study of DNA damage in breast cancer seems to be a more 
appropriate avenue to explore with respect to the NRMT1 
cancer mutants that I characterized in Chapter II. 
Within the list of potential NRMT1 substrates, only a 
handful are involved in the DNA damage response, including 
Rb, DDB2, PARP3, and BAP1 (50).  At present, it is unknown 
whether or how methylation by NRMT1 facilitates the 
function of these targets.  Methylation could affect the 
localization of these targets to sites of DNA damage 
through direct DNA binding; or, it could regulate protein-
protein interactions crucial for downstream functions.  For 
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example, while methylation of DDB2 is necessary for its 
recruitment to sites of DNA damage (52), the methylation of 
PARP3 is not (118). 
Thus, a preliminary working model for how NRMT1 might 
function during DNA damage in breast cancer cells is 
depicted in Figure 22.  DNA damaging agents, such as 
etoposide, cause DSBs, resulting in p53 activation and 
transcriptional upregulation of DNA repair proteins, which 
can lead to cell survival (178).  One potential role for 
NRMT1 could involve the maintenance of p53 expression.  
Additionally, NRMT1 may be exerting influence over the DNA 
damage response through trimethylation of an unknown 
protein.  This methylation could facilitate either the 
localization of DNA repair proteins to sites of DNA damage, 
or regulate protein-protein interactions, which would 
result in downstream localization to the DSBs.  Since the 
N209I and P211S mutants do not result in rescue of N-
terminal trimethylation in cells, I hypothesize that these 
mutants will be incapable of rescuing the sensitivity 





























Figure 22. Model of NRMT1 in the DNA damage response. 
The role of NRMT1 in the DNA damage response remains 
unclear, with the following model proposed.  Upon 
doxorubicin treatment, p53 becomes activated and 
upregulates the expression of DNA repair proteins, leading 
to cell survival.  In response to doxorubicin, NRMT1 is 
proposed to influence the expression of p53, which would 
further increase DNA repair protein (some of which are 
verified NRMT1 substrates) expression and cell survival.  
NRMT1 may be exerting additional clout over this response 
through trimethylation of an unknown protein, which could 
be one of its repair protein substrates, leading to further 
cell survival.  As the NRMT1 mutants N209I and P211S do not 
rescue N-terminal trimethylation in cells, they are 
hypothesized to be incapable of rescuing the effects of the 
DNA damage and are therefore proposed to be nonfunctional 
in this context. 
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Developing More Tools to Study NRMT1 Substrates 
 
There are many putative targets of NRMT1, and one 
challenge is to identify specific targets in different 
pathways.  One area that needs attention is the lack of 
antibodies against other NRMT1 substrate consensus 
sequences, besides the existing SPK antibodies.  An example 
would include antibodies that recognize the trimethylated 
PPK consensus (for targets such as Rb).  A more tedious, 
but unbiased, approach would be to employ mass spectrometry 
to determine the substrate(s) differentially methylated by 
NRMT1 during various cellular processes, such as the DNA 
damage response. 
Once these differentially methylated substrates are 
identified, they can then be tested for their importance in 
the pathway.  As an example, suppose there was a substrate 
of NRMT1 named “SubX,” for simplicity.  CRISPR/Cas9 
methodology could then be utilized to create a knockout 
cell line lacking SubX.  Preliminary studies could then 
quickly assess the importance of SubX in a pathway. 
Subsequently, the knockout cell line would then be 
rescued with either wild type SubX or a non-methylatable 
mutant.  This would further allow me to determine the 
importance of methylation of the protein in the pathway. 
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Finally, generation of knockin mice for this mutant will 
allow the determination of its physiological importance. 
 
Future Studies for NRMT1 and Oxidative Stress 
 
 One important observation gained from the studies of 
NRMT1 KO mice and MEFs is their increased sensitivity 
towards oxidative stress (51).  Thus, NRMT1 could also act 
through this pathway to influence cell survival in response 
to certain chemotherapeutic drugs which cause oxidative 
stress (179,180). 
As an initial study, I would use the H2DCF-DA reagent 
(Invitrogen) to detect total cellular ROS levels in NRMT1-
deficient cells in response to drugs, or other insults 
(181).  Using the MitoSOX™ Red reagent (Thermo Fisher 
Scientific), which is oxidized by superoxide, would further 
allow me to examine mitochondrial ROS generation (182).  If 
these preliminary experiments proved fruitful, one could 
then utilize state-of-the-art techniques, such as electron 
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Figure 23. Mutant NRMT1 SPK methylation pattern. 
Whole cell lysates from the five featured cell lines were 
probed with the tri-SPK (me3RCC1) antibody.  Band indicated 
by asterisk is RCC1.  NRMT1 recognizes many substrates with 
a variety of consensus sequences; only a handful of those 
have the SPK consensus sequence.  a-tubulin included as a 












Figure 24. Viability studies of HCT116 cells. 
Four sets of triplicates were made for each of the five 
HCT116 cell lines.  Cells were seeded at a density of 1000 
cells per well in 96-well plates.  On the day of plating 
(day 0), 20 µl of Aqueous One Solution (Promega, Madison, 
WI) was added to the first set of triplicates for each cell 
line, and the absorbance at 490 nm was read after two 
hours.  Readings were also taken on days 1, 3, and 5.  (A-
I) Raw absorbance values are shown on the Y-axis.  Each 










Figure 25. Viability assay of doxorubicin-treated cont. and 
NRMT1 KO cells. 
2.4 X 104 cells per well were seeded into 24-well plates.  
Three sets of triplicates were made for cont. and NRMT1 KO 
cells.  CellTiter was performed on cells that were treated 
with 0.1 or 1 µM doxorubicin (or the untreated controls) for 
24 hours.  Following treatment, 80 µl of Aqueous One 
Solution was added to each well, and the absorbance at 490 
nm was read after two hours.  Y-axis units are arbitrary 














Figure 26. Viability assay of doxorubicin-treated cells. 
2.4 X 104 cells per well were seeded into 24-well plates.  
Two sets of triplicates were made for each cell line.  
CellTiter was performed on cells that were treated with 1 µM 
doxorubicin (or the untreated controls) for 24 hours.  
Following treatment, 80 µl of Aqueous One Solution was added 
to each well, and the absorbance at 490 nm was read after 
two hours.  Y-axis units are arbitrary units of absorbance 








Figure 27. siRNA Studies in HCT116 cells. 
2.4 X 104 cells per well were seeded into 24-well plates.  
Cells were grown until they reached 70% confluency (two 
days after seeding).  Cells were transfected with 10 pM 
siRNA.  Media was changed 21 hours after transfections.  
Two days later, cells were treated with either 1 µM 
doxorubicin or 250 µM etoposide (untreated controls were 
included, as indicated in the figure) for six hours.  Cell 
lysates were collected immediately following treatment.  
Lysates were subjected to western blot analysis, probing 
with the indicated antibodies.  Experiment was done once. 
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APPENDICES: WORK DISCLAIMER 
 
The data appearing in this dissertation are my own and 
were performed by me.  Exceptions to this are Figures 4-6 
and 8-10.  Figures 4, 9, and 10 were performed by John 
Tooley, State University of New York at Buffalo.  The 
molecular modeling exhibited in Figure 8 was performed by 
Janusz Petkowski, Massachusetts Institute of Technology.  
The graph in Figure 5 was created by me but is based upon 
the raw mass spectrometry data produced by the University 
of Louisville Mass Spectrometry Core Laboratory, which is 
displayed in Figure 6. 
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PROFESSIONAL ASSOCIATIONS 
American Chemical Society 
American Society for Biochemistry and Molecular Biology 
Kentucky Academy of Science 
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National Science Teachers Association 
Society for College Science Teachers 
 
SERVICE AND EXTRACURRICULAR ACTIVIES 
2016-present: Science fair judge for the Louisville 
Regional Science & Engineering Fair 
2015-present: Science fair judge for the DuPont 
Manual Regional Science Fair 
2015-16:   Graduate Student Council departmental 
representative 
2012-13:   Science community outreach with MSSU 
Chemistry Club 
2011-13:  Vice President of MSSU Biology Club 
2011-13: Science fair judge for the Missouri Southern 
Regional Science Fair 
2011: Volunteer for Joplin tornado disaster relief 
efforts 
2010-12: Deer aging for the Missouri Department of 
Conservation 
